



**ANNUAL STATEMENT  
FOR THE YEAR ENDING DECEMBER 31, 2020  
OF THE CONDITION AND AFFAIRS OF THE**

## **Elixir Insurance Company**

(Name)

NAIC Group Code 00000 (Current Period) , 00000 (Prior Period) NAIC Company Code 12747 Employer's ID Number 20-4308924

Organized under the Laws of Ohio, State of Domicile or Port of Entry Ohio

Country of Domicile \_\_\_\_\_ United States \_\_\_\_\_

Licensed as business type:  Life, Accident & Health  Property/Casualty  Hospital, Medical & Dental Service or Indemnity  
 Dental Service Corporation  Vision Service Corporation  Health Maintenance Organization  
 Other  Is HMO, Federally Qualified? Yes  No

Incorporated/Organized 02/08/2006 Commenced Business 01/01/2007

Statutory Home Office \_\_\_\_\_, 2181 East Aurora Road \_\_\_\_\_, Twinsburg, OH, US 44087  
(Street and Number) \_\_\_\_\_, (City or Town, State, Country and Zip Code)

Main Administrative Office \_\_\_\_\_ 2181 East Aurora Road  
(Street and Number)  
Twinsburg, OH, US 44087 \_\_\_\_\_ 330-405-8089  
(City or Town, State, Country and Zip Code) (Area Code) (Telephone Number)

Mail Address 2181 East Aurora Road, Twinsburg, OH, US 44087  
(Street and Number or P.O. Box) (City or Town, State, Country and Zip Code)

Primary Location of Books and Records \_\_\_\_\_ 2181 East Aurora Road \_\_\_\_\_  
(Street and Number)  
Twinsburg, OH, US 44087 \_\_\_\_\_, \_\_\_\_\_ 330-405-8089 \_\_\_\_\_  
(City or Town, State, Country and Zip Code) (Area Code) (Telephone Number) (Extension)

Internet Web Site Address www.envisionrx.com  
Statutory Statement Contact Scott David Gonia CPA, 866-250-2005  
(Name) (Area Code) (Telephone Number) (Extension)  
eicaccounting@envisionrx.com 330-486-4801  
(E-Mail Address) (Fax Number)

# OFFICERS

Name	Title	Name	Title
Daniel Dean Robson #	President	Scott David Gonia	Treasurer
Robert Burns Weinberg	Senior Vice President, General Counsel & Secretary	Thomas John Welsh	Chief Financial Officer & Executive Vice President

## OTHER OFFICERS

## **DIRECTORS OR TRUSTEES**

State of ..... Ohio.....

The officers of this reporting entity, being duly sworn, each depose and say that they are the described officers of said reporting entity, and that on the reporting period stated above, all of the herein described assets were the absolute property of the said reporting entity, free and clear from any liens or claims thereon, except as herein stated, and that this statement, together with related exhibits, schedules and explanations therein contained, annexed or referred to, is a full and true statement of all the assets and liabilities and of the condition and affairs of the said reporting entity as of the reporting period stated above, and of its income and deductions therefrom for the period ended, and have been completed in accordance with the NAIC *Annual Statement Instructions and Accounting Practices and Procedures* manual except to the extent that: (1) state law may differ; or, (2) that state rules or regulations require differences in reporting not related to accounting practices and procedures, according to the best of their information, knowledge and belief, respectively. Furthermore, the scope of this attestation by the described officers also includes the related corresponding electronic filing with the NAIC, when required, that is an exact copy (except for formatting differences due to electronic filing) of the enclosed statement. The electronic filing may be requested by various regulators in lieu of or in addition to the enclosed statement.

---

Thomas John Welsh  
Chief Financial Officer & Executive Vice President

Scott David Gonia  
Treasurer

**Senior Vice President, General Counsel &  
Secretary**

Subscribed and sworn to before me this  
\_\_\_\_ day of \_\_\_\_\_,

a. Is this an original filing? Yes [  ] No [  ]  
b. If no:  
1. State the amendment number \_\_\_\_\_  
2. Date filed \_\_\_\_\_  
3. Number of pages attached \_\_\_\_\_

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**ASSETS**

	Current Year			Prior Year
	1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1. Bonds (Schedule D).....	6,997,806		6,997,806	7,033,597
2. Stocks (Schedule D):				
2.1 Preferred stocks .....	0		0	0
2.2 Common stocks .....	0		0	0
3. Mortgage loans on real estate (Schedule B):				
3.1 First liens .....			0	0
3.2 Other than first liens .....			0	0
4. Real estate (Schedule A):				
4.1 Properties occupied by the company (less \$ ..... encumbrances).....			0	0
4.2 Properties held for the production of income (less \$ ..... encumbrances) .....			0	0
4.3 Properties held for sale (less \$ ..... encumbrances) .....			0	0
5. Cash (\$ .....156,357,022 , Schedule E-Part 1), cash equivalents (\$ .....0 , Schedule E-Part 2) and short-term investments (\$ .....0 , Schedule DA).....	156,357,022		156,357,022	143,134,866
6. Contract loans (including \$ ..... premium notes).....			0	0
7. Derivatives (Schedule DB).....	0		0	0
8. Other invested assets (Schedule BA).....	0		0	0
9. Receivables for securities .....			0	0
10. Securities lending reinvested collateral assets (Schedule DL).....			0	0
11. Aggregate write-ins for invested assets .....	0	0	0	0
12. Subtotals, cash and invested assets (Lines 1 to 11) .....	163,354,828	0	163,354,828	150,168,463
13. Title plants less \$ ..... charged off (for Title insurers only).....			0	0
14. Investment income due and accrued .....	40,913		40,913	37,658
15. Premiums and considerations:				
15.1 Uncollected premiums and agents' balances in the course of collection .....	4,965,459		4,965,459	3,304,869
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due (including \$ ..... earned but unbilled premiums).....			0	0
15.3 Accrued retrospective premiums (\$ .....105,508,937 ) and contracts subject to redetermination (\$ ..... ) .....	105,508,937		105,508,937	159,915,578
16. Reinsurance:				
16.1 Amounts recoverable from reinsurers .....			0	0
16.2 Funds held by or deposited with reinsured companies .....	519,543		519,543	613,756
16.3 Other amounts receivable under reinsurance contracts .....	5,345,247	5,345,247	0	350,462
17. Amounts receivable relating to uninsured plans .....	273,248,027		273,248,027	389,514,427
18.1 Current federal and foreign income tax recoverable and interest thereon .....			0	0
18.2 Net deferred tax asset.....	3,021,497		3,021,497	281,791
19. Guaranty funds receivable or on deposit .....			0	0
20. Electronic data processing equipment and software.....			0	0
21. Furniture and equipment, including health care delivery assets (\$ ..... ) .....			0	0
22. Net adjustment in assets and liabilities due to foreign exchange rates .....			0	0
23. Receivables from parent, subsidiaries and affiliates .....			0	0
24. Health care (\$ ..... ) and other amounts receivable.....	344,091		344,091	83,206
25. Aggregate write-ins for other-than-invested assets .....	476,988	476,988	0	0
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25).....	556,825,530	5,822,235	551,003,295	704,270,210
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts.....			0	0
28. Total (Lines 26 and 27) .....	556,825,530	5,822,235	551,003,295	704,270,210
<b>DETAILS OF WRITE-INS</b>				
1101. ....			0	0
1102. ....			0	0
1103. ....			0	0
1198. Summary of remaining write-ins for Line 11 from overflow page .....	0	0	0	0
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above) .....	0	0	0	0
2501. Prepaid Expenses.....	476,988	476,988	0	0
2502. ....			0	0
2503. ....			0	0
2598. Summary of remaining write-ins for Line 25 from overflow page .....	0	0	0	0
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above) .....	476,988	476,988	0	0

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**LIABILITIES, CAPITAL AND SURPLUS**

	Current Year			Prior Year
	1 Covered	2 Uncovered	3 Total	4 Total
1. Claims unpaid (less \$ 903,836 reinsurance ceded)	128,517,229		128,517,229	178,682,051
2. Accrued medical incentive pool and bonus amounts			0	0
3. Unpaid claims adjustment expenses	3,303,791		3,303,791	2,448,357
4. Aggregate health policy reserves, including the liability of \$ for medical loss ratio rebate per the Public Health Service Act			0	0
5. Aggregate life policy reserves			0	0
6. Property/casualty unearned premium reserves			0	0
7. Aggregate health claim reserves			0	0
8. Premiums received in advance	2,461,843		2,461,843	3,023,811
9. General expenses due or accrued	188,428		188,428	675,822
10.1 Current federal and foreign income tax payable and interest thereon (including \$ on realized capital gains (losses))			0	1,764,234
10.2 Net deferred tax liability			0	0
11. Ceded reinsurance premiums payable	1,787,370		1,787,370	1,875,125
12. Amounts withheld or retained for the account of others			0	0
13. Remittances and items not allocated			0	0
14. Borrowed money (including \$ current) and interest thereon \$ (including \$ current)			0	0
15. Amounts due to parent, subsidiaries and affiliates	325,174,224		325,174,224	445,095,143
16. Derivatives		0	0	0
17. Payable for securities			0	0
18. Payable for securities lending			0	0
19. Funds held under reinsurance treaties (with \$ authorized reinsurers, \$ 3,406,380 unauthorized reinsurers and \$ certified reinsurers)	3,406,380		3,406,380	3,808,575
20. Reinsurance in unauthorized and certified (\$ companies)			0	0
21. Net adjustments in assets and liabilities due to foreign exchange rates			0	0
22. Liability for amounts held under uninsured plans	11,223,439		11,223,439	12,115,195
23. Aggregate write-ins for other liabilities (including \$ current)	0	0	0	0
24. Total liabilities (Lines 1 to 23)	476,062,704		476,062,704	649,488,313
25. Aggregate write-ins for special surplus funds	XXX	XXX	0	7,669,803
26. Common capital stock	XXX	XXX	2,000,000	2,000,000
27. Preferred capital stock	XXX	XXX		0
28. Gross paid in and contributed surplus	XXX	XXX	104,200,000	61,700,000
29. Surplus notes	XXX	XXX	0	0
30. Aggregate write-ins for other-than-special surplus funds	XXX	XXX	0	0
31. Unassigned funds (surplus)	XXX	XXX	(31,259,409)	(16,587,906)
32. Less treasury stock, at cost:				
32.1 shares common (value included in Line 26 \$ )	XXX	XXX		0
32.2 shares preferred (value included in Line 27 \$ )	XXX	XXX		0
33. Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	74,940,591	54,781,897
34. Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	551,003,295	704,270,210
<b>DETAILS OF WRITE-INS</b>				
2301.			0	0
2302.			0	0
2303.			0	0
2398. Summary of remaining write-ins for Line 23 from overflow page	0	0	0	0
2399. Totals (Lines 2301 through 2303 plus 2398) (Line 23 above)	0	0	0	0
2501. Reserve for ACA Section 9010 Fee.	XXX	XXX	0	7,669,803
2502.	XXX	XXX		0
2503.	XXX	XXX		0
2598. Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX	0	0
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above)	XXX	XXX	0	7,669,803
3001.	XXX	XXX		0
3002.	XXX	XXX		0
3003.	XXX	XXX		0
3098. Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX	0	0
3099. Totals (Lines 3001 through 3003 plus 3098) (Line 30 above)	XXX	XXX	0	0

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**STATEMENT OF REVENUE AND EXPENSES**

	Current Year		Prior Year
	1 Uncovered	2 Total	3 Total
1. Member Months.....	XXX	.10,909,167	.8,020,563
2. Net premium income (including \$ .....0 non-health premium income).....	XXX	.590,533,060	.424,976,399
3. Change in unearned premium reserves and reserve for rate credits .....	XXX		0
4. Fee-for-service (net of \$ .....medical expenses).....	XXX		0
5. Risk revenue .....	XXX		0
6. Aggregate write-ins for other health care related revenues .....	XXX	.0	0
7. Aggregate write-ins for other non-health revenues .....	XXX	.0	0
8. Total revenues (Lines 2 to 7).....	XXX	.590,533,060	.424,976,399
<b>Hospital and Medical:</b>			
9. Hospital/medical benefits .....			0
10. Other professional services .....			0
11. Outside referrals .....			0
12. Emergency room and out-of-area .....			0
13. Prescription drugs .....		.584,659,958	.403,804,688
14. Aggregate write-ins for other hospital and medical.....	.0	.0	0
15. Incentive pool, withhold adjustments and bonus amounts.....			0
16. Subtotal (Lines 9 to 15).....	.0	.584,659,958	.403,804,688
<b>Less:</b>			
17. Net reinsurance recoveries .....		.8,548,135	.11,544,609
18. Total hospital and medical (Lines 16 minus 17).....	.0	.576,111,823	.392,260,079
19. Non-health claims (net).....			0
20. Claims adjustment expenses, including \$ .....0 cost containment expenses.....		.3,775,693	.3,856,850
21. General administrative expenses.....		.33,006,445	.20,049,571
22. Increase in reserves for life and accident and health contracts (including \$ ..... increase in reserves for life only).....		.0	0
23. Total underwriting deductions (Lines 18 through 22).....	.0	.612,893,961	.416,166,500
24. Net underwriting gain or (loss) (Lines 8 minus 23).....	XXX	.(22,360,901)	.8,809,899
25. Net investment income earned (Exhibit of Net Investment Income, Line 17).....		.199,506	.973,927
26. Net realized capital gains (losses) less capital gains tax of \$ .....			0
27. Net investment gains (losses) (Lines 25 plus 26).....	.0	.199,506	.973,927
28. Net gain or (loss) from agents' or premium balances charged off [(amount recovered \$ .....11,593 ) (amount charged off \$ .....2,501,593 )] .....		.(2,490,000)	(1,762,500)
29. Aggregate write-ins for other income or expenses .....	.0	.0	0
30. Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29).....	XXX	.(24,651,395)	.8,021,326
31. Federal and foreign income taxes incurred .....	XXX		.1,764,234
32. Net income (loss) (Lines 30 minus 31).....	XXX	.(24,651,395)	.6,257,092
<b>DETAILS OF WRITE-INS</b>			
0601.....	XXX		0
0602.....	XXX		0
0603.....	XXX		0
0698. Summary of remaining write-ins for Line 6 from overflow page .....	XXX	.0	0
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above).....	XXX	.0	0
0701.....	XXX		0
0702.....	XXX		0
0703.....	XXX		0
0798. Summary of remaining write-ins for Line 7 from overflow page .....	XXX	.0	0
0799. Totals (Lines 0701 through 0703 plus 0798) (Line 7 above).....	XXX	.0	0
1401.....			0
1402.....			0
1403.....			0
1498. Summary of remaining write-ins for Line 14 from overflow page .....	.0	.0	0
1499. Totals (Lines 1401 through 1403 plus 1498) (Line 14 above).....	0	0	0
2901. Discount on Early Claims Payment.....		.36,081,955	0
2902. Loss on Sale of CMS Receivables.....		.(36,081,955)	0
2903.....			0
2998. Summary of remaining write-ins for Line 29 from overflow page .....	.0	.0	0
2999. Totals (Lines 2901 through 2903 plus 2998) (Line 29 above).....	0	0	0

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**STATEMENT OF REVENUE AND EXPENSES (Continued)**

	1 Current Year	2 Prior Year
<b>CAPITAL &amp; SURPLUS ACCOUNT</b>		
33. Capital and surplus prior reporting year .....	.54,781,897	51,821,232
34. Net income or (loss) from Line 32 .....	(24,651,395)	6,257,092
35. Change in valuation basis of aggregate policy and claim reserves .....	0	0
36. Change in net unrealized capital gains (losses) less capital gains tax of \$ .....	0	0
37. Change in net unrealized foreign exchange capital gain or (loss) .....	0	0
38. Change in net deferred income tax .....	2,739,706	77,611
39. Change in nonadmitted assets .....	(429,617)	(3,374,038)
40. Change in unauthorized and certified reinsurance .....	0	0
41. Change in treasury stock .....	0	0
42. Change in surplus notes .....	0	0
43. Cumulative effect of changes in accounting principles .....	0	0
44. Capital Changes:		
44.1 Paid in .....	0	0
44.2 Transferred from surplus (Stock Dividend) .....	0	0
44.3 Transferred to surplus .....	0	0
45. Surplus adjustments:		
45.1 Paid in .....	42,500,000	0
45.2 Transferred to capital (Stock Dividend) .....	0	0
45.3 Transferred from capital .....	0	0
46. Dividends to stockholders .....	0	0
47. Aggregate write-ins for gains or (losses) in surplus .....	0	0
48. Net change in capital and surplus (Lines 34 to 47) .....	.20,158,694	2,960,665
49. Capital and surplus end of reporting year (Line 33 plus 48)	74,940,591	54,781,897
<b>DETAILS OF WRITE-INS</b>		
4701. ....	0	0
4702. ....	0	0
4703. ....	0	0
4798. Summary of remaining write-ins for Line 47 from overflow page .....	0	0
4799. Totals (Lines 4701 through 4703 plus 4798) (Line 47 above)	0	0

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**CASH FLOW**

<b>Cash from Operations</b>		<b>1 Current Year</b>	<b>2 Prior Year</b>
1. Premiums collected net of reinsurance		642,629,388	394,263,837
2. Net investment income		260,999	1,162,120
3. Miscellaneous income		98,648	(613,756)
4. Total (Lines 1 through 3)		642,989,035	394,812,201
5. Benefit and loss related payments		626,276,645	341,431,244
6. Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		0	0
7. Commissions, expenses paid and aggregate write-ins for deductions		(76,470,546)	173,695,161
8. Dividends paid to policyholders		0	0
9. Federal and foreign income taxes paid (recovered) net of \$ tax on capital gains (losses)		1,764,234	1,289,818
10. Total (Lines 5 through 9)		551,570,333	516,416,222
11. Net cash from operations (Line 4 minus Line 10)		91,418,702	(121,604,021)
<b>Cash from Investments</b>			
12. Proceeds from investments sold, matured or repaid:		700,000	4,160,000
12.1 Bonds		0	0
12.2 Stocks		0	0
12.3 Mortgage loans		0	0
12.4 Real estate		0	0
12.5 Other invested assets		0	0
12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		0	0
12.7 Miscellaneous proceeds		0	0
12.8 Total investment proceeds (Lines 12.1 to 12.7)		700,000	4,160,000
13. Cost of investments acquired (long-term only):		728,957	4,091,067
13.1 Bonds		0	0
13.2 Stocks		0	0
13.3 Mortgage loans		0	0
13.4 Real estate		0	0
13.5 Other invested assets		0	0
13.6 Miscellaneous applications		0	0
13.7 Total investments acquired (Lines 13.1 to 13.6)		728,957	4,091,067
14. Net increase (decrease) in contract loans and premium notes		0	0
15. Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)		(28,957)	68,933
<b>Cash from Financing and Miscellaneous Sources</b>			
16. Cash provided (applied):		0	0
16.1 Surplus notes, capital notes		0	0
16.2 Capital and paid in surplus, less treasury stock		42,500,000	0
16.3 Borrowed funds		0	0
16.4 Net deposits on deposit-type contracts and other insurance liabilities		0	0
16.5 Dividends to stockholders		0	0
16.6 Other cash provided (applied)		(120,667,589)	149,953,167
17. Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)		(78,167,589)	149,953,167
<b>RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS</b>			
18. Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)		13,222,156	28,418,079
19. Cash, cash equivalents and short-term investments:		143,134,866	114,716,786
19.1 Beginning of year		156,357,022	143,134,866
19.2 End of year (Line 18 plus Line 19.1)		0	0

## ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company

## ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

## ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company

## UNDERWRITING AND INVESTMENT EXHIBIT

## PART 1 - PREMIUMS

Line of Business	1 Direct Business	2 Reinsurance Assumed	3 Reinsurance Ceded	4 Net Premium Income (Cols. 1+2-3)
1. Comprehensive (hospital and medical) .....				.0
2. Medicare Supplement .....				.0
3. Dental only.....				.0
4. Vision only.....				.0
5. Federal Employees Health Benefits Plan .....				.0
6. Title XVIII - Medicare .....				.0
7. Title XIX - Medicaid.....				.0
8. Other health.....	603,376,693		12,843,633	590,533,060
9. Health subtotal (Lines 1 through 8) .....	603,376,693	0	12,843,633	590,533,060
10. Life .....				.0
11. Property/casualty.....				.0
12. Totals (Lines 9 to 11)	603,376,693	0	12,843,633	590,533,060

## ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company

## UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2 – CLAIMS INCURRED DURING THE YEAR

	1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other Health	10 Other Non- Health
1. Payments during the year:										
1.1 Direct	634,709,476								634,709,476	
1.2 Reinsurance assumed	0								0	
1.3 Reinsurance ceded	8,432,831								8,432,831	
1.4 Net	626,276,645	0	0	0	0	0	0	0	626,276,645	0
2. Paid medical incentive pools and bonuses	0									
3. Claim liability December 31, current year from Part 2A:										
3.1 Direct	129,421,065	0	0	0	0	0	0	0	129,421,065	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	903,836	0	0	0	0	0	0	0	903,836	0
3.4 Net	128,517,229	0	0	0	0	0	0	0	128,517,229	0
4. Claim reserve December 31, current year from Part 2D:										
4.1 Direct	0									
4.2 Reinsurance assumed	0									
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	0	0	0	0	0	0	0	0	0	0
5. Accrued medical incentive pools and bonuses, current year	0									
6. Net healthcare receivables (a)	0									
7. Amounts recoverable from reinsurers December 31, current year	0									
8. Claim liability December 31, prior year from Part 2A:										
8.1 Direct	179,470,584	0	0	0	0	0	0	0	179,470,584	0
8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
8.3 Reinsurance ceded	788,532	0	0	0	0	0	0	0	788,532	0
8.4 Net	178,682,052	0	0	0	0	0	0	0	178,682,052	0
9. Claim reserve December 31, prior year from Part 2D:										
9.1 Direct	0	0	0	0	0	0	0	0	0	0
9.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
9.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
9.4 Net	0	0	0	0	0	0	0	0	0	0
10. Accrued medical incentive pools and bonuses, prior year	0									
11. Amounts recoverable from reinsurers December 31, prior year	0	0	0	0	0	0	0	0	0	0
12. Incurred benefits:										
12.1 Direct	584,659,957	0	0	0	0	0	0	0	584,659,957	0
12.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
12.3 Reinsurance ceded	8,548,135	0	0	0	0	0	0	0	8,548,135	0
12.4 Net	576,111,822	0	0	0	0	0	0	0	576,111,822	0
13. Incurred medical incentive pools and bonuses	0	0	0	0	0	0	0	0	0	0

(a) Excludes \$ ..... loans or advances to providers not yet expensed.

## ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company

## UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1 Total	2 Comprehensive (Hospital and Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefits Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other Health	10 Other Non-Health
1. Reported in Process of Adjustment:										
1.1. Direct	126,901,120								126,901,120	
1.2. Reinsurance assumed	0									
1.3. Reinsurance ceded	903,836								903,836	
1.4. Net	125,997,284	0	0	0	0	0	0	0	125,997,284	0
2. Incurred but Unreported:										
2.1. Direct	2,519,945								2,519,945	
2.2. Reinsurance assumed	0									
2.3. Reinsurance ceded	0									
2.4. Net	2,519,945	0	0	0	0	0	0	0	2,519,945	0
3. Amounts Withheld from Paid Claims and Capitations:										
3.1. Direct	0									
3.2. Reinsurance assumed	0									
3.3. Reinsurance ceded	0									
3.4. Net	0	0	0	0	0	0	0	0	0	0
4. TOTALS:										
4.1. Direct	129,421,065	0	0	0	0	0	0	0	129,421,065	0
4.2. Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3. Reinsurance ceded	903,836	0	0	0	0	0	0	0	903,836	0
4.4. Net	128,517,229	0	0	0	0	0	0	0	128,517,229	0

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**UNDERWRITING AND INVESTMENT EXHIBIT**

**PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR-NET OF REINSURANCE**

Line of Business	Claims Paid During the Year		Claim Reserve and Claim Liability December 31 of Current Year		5 Claims Incurred in Prior Years (Columns 1 + 3)	6 Estimated Claim Reserve and Claim Liability December 31 of Prior Year
	1 On Claims Incurred Prior to January 1 of Current Year	2 On Claims Incurred During the Year	3 On Claims Unpaid December 31 of Prior Year	4 On Claims Incurred During the Year		
1. Comprehensive (hospital and medical) .....					0	.0
2. Medicare Supplement .....					0	.0
3. Dental Only .....					0	.0
4. Vision Only .....					0	.0
5. Federal Employees Health Benefits Plan .....					0	.0
6. Title XVIII - Medicare .....					0	.0
7. Title XIX - Medicaid .....					0	.0
8. Other health .....	173,029,953	453,246,692		128,517,229	173,029,953	178,682,051
9. Health subtotal (Lines 1 to 8) .....	173,029,953	453,246,692	.0	128,517,229	173,029,953	178,682,051
10. Healthcare receivables (a) .....					0	.0
11. Other non-health .....					0	.0
12. Medical incentive pools and bonus amounts .....					0	.0
13. Totals (Lines 9-10+11+12)	173,029,953	453,246,692	0	128,517,229	173,029,953	178,682,051

(a) Excludes \$ ..... loans or advances to providers not yet expensed.

Pt 2C - Sn A - Paid Claims - Comp

**NONE**

Pt 2C - Sn A - Paid Claims - MS

**NONE**

Pt 2C - Sn A - Paid Claims - DO

**NONE**

Pt 2C - Sn A - Paid Claims - VO

**NONE**

Pt 2C - Sn A - Paid Claims - FE

**NONE**

Pt 2C - Sn A - Paid Claims - XV

**NONE**

Pt 2C - Sn A - Paid Claims - XI

**NONE**

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**UNDERWRITING AND INVESTMENT EXHIBIT**

**PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS**

(\$000 Omitted)

**Section A - Paid Health Claims - Other**

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2016	2 2017	3 2018	4 2019	5 2020
1. Prior .....	804,926	805,410	806,018	805,823	806,077
2. 2016.....	197,084	221,016	220,411	220,765	220,816
3. 2017.....	XXX.....	130,524	156,334	156,040	155,994
4. 2018.....	XXX.....	XXX.....	234,713	363,372	361,962
5. 2019.....	XXX.....	XXX.....	XXX.....	212,908	387,089
6. 2020.....	XXX.....	XXX.....	XXX.....	XXX.....	453,247

**Section B – Incurred Health Claims - Other**

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2016	2 2017	3 2018	4 2019	5 2020
1. Prior .....	804,926	805,410	806,018	805,823	806,077
2. 2016.....	222,000	221,016	220,411	220,765	220,816
3. 2017.....	XXX.....	156,286	156,334	156,040	155,994
4. 2018.....	XXX.....	XXX.....	362,566	363,372	361,962
5. 2019.....	XXX.....	XXX.....	XXX.....	391,588	387,089
6. 2020.....	XXX.....	XXX.....	XXX.....	XXX.....	581,764

**Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio – Other**

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payments	3 Claim Adjustment Expense Payments	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2+3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2016.....	235,910	220,816	4,888	2.2	225,704	95.7			225,704	95.7
2. 2017.....	170,333	155,994	6,178	4.0	162,172	95.2			162,172	95.2
3. 2018.....	393,702	361,962	4,406	1.2	366,368	93.1			366,368	93.1
4. 2019.....	424,976	387,089	3,857	1.0	390,946	92.0			390,946	92.0
5. 2020.....	590,533	453,247	472	0.1	453,719	76.8	128,517	3,304	585,540	99.2

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**UNDERWRITING AND INVESTMENT EXHIBIT**

**PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS**

(\$000 Omitted)

**Section A - Paid Health Claims - Grand Total**

Year in Which Losses Were Incurred	Cumulative Net Amounts Paid				
	1 2016	2 2017	3 2018	4 2019	5 2020
1. Prior .....	804,926	805,410	806,018	805,823	806,077
2. 2016.....	197,084	221,016	220,411	220,765	220,816
3. 2017.....	XXX.....	130,524	156,334	156,040	155,994
4. 2018.....	XXX.....	XXX.....	234,713	363,372	361,962
5. 2019.....	XXX.....	XXX.....	XXX.....	212,908	387,089
6. 2020	XXX	XXX	XXX	XXX	453,247

**Section B - Incurred Health Claims - Grand Total**

Year in Which Losses Were Incurred	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuses Outstanding at End of Year				
	1 2016	2 2017	3 2018	4 2019	5 2020
1. Prior .....	804,926	805,410	806,018	805,823	806,077
2. 2016.....	222,000	221,016	220,411	220,765	220,816
3. 2017.....	XXX.....	156,286	156,334	156,040	155,994
4. 2018.....	XXX.....	XXX.....	362,566	363,372	361,962
5. 2019.....	XXX.....	XXX.....	XXX.....	391,588	387,089
6. 2020	XXX	XXX	XXX	XXX	581,764

**Section C – Incurred Year Health Claims and Claims Adjustment Expense Ratio – Grand Total**

Years in which Premiums were Earned and Claims were Incurred	1 Premiums Earned	2 Claims Payments	3 Claim Adjustment Expense Payments (Col. 3/2) Percent	4 (Col. 3/2) Percent	5 Claim and Claim Adjustment Expense Payments (Col. 2+3)	6 (Col. 5/1) Percent	7 Claims Unpaid	8 Unpaid Claims Adjustment Expenses	9 Total Claims and Claims Adjustment Expense Incurred (Col. 5+7+8)	10 (Col. 9/1) Percent
1. 2016.....	235,910	220,816	4,888	2.2	225,704	95.7	0	0	225,704	95.7
2. 2017.....	170,333	155,994	6,178	4.0	162,172	95.2	0	0	162,172	95.2
3. 2018.....	393,702	361,962	4,406	1.2	366,368	93.1	0	0	366,368	93.1
4. 2019.....	424,976	387,089	3,857	1.0	390,946	92.0	0	0	390,946	92.0
5. 2020	590,533	453,247	472	0.1	453,719	76.8	128,517	3,304	585,540	99.2

Pt 2C - Sn B - Incurred Claims - Comp

**NONE**

Pt 2C - Sn B - Incurred Claims - MS

**NONE**

Pt 2C - Sn B - Incurred Claims - DO

**NONE**

Pt 2C - Sn B - Incurred Claims - VO

**NONE**

Pt 2C - Sn B - Incurred Claims - FE

**NONE**

Pt 2C - Sn B - Incurred Claims - XV

**NONE**

Pt 2C - Sn B - Incurred Claims - XI

**NONE**

Part 2C - Sn C - Claims Expense Ratio Co

**NONE**

Part 2C - Sn C - Claims Expense Ratio MS

**NONE**

Part 2C - Sn C - Claims Expense Ratio DO

**NONE**

Part 2C - Sn C - Claims Expense Ratio VO

**NONE**

Part 2C - Sn C - Claims Expense Ratio FE

**NONE**

Part 2C - Sn C - Claims Expense Ratio XV

**NONE**

Part 2C - Sn C - Claims Expense Ratio XI

**NONE**

## ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company

## UNDERWRITING AND INVESTMENT EXHIBIT

## PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1 Total	2 Comprehensive (Hospital & Medical)	3 Medicare Supplement	4 Dental Only	5 Vision Only	6 Federal Employees Health Benefit Plan	7 Title XVIII Medicare	8 Title XIX Medicaid	9 Other
1. Unearned premium reserves	.0								
2. Additional policy reserves (a)	.0								
3. Reserve for future contingent benefits	.0								
4. Reserve for rate credits or experience rating refunds (including \$ ..... for investment income)	.0								
5. Aggregate write-ins for other policy reserves	.0	.0	.0	0	.0	.0	0	0	.0
6. Totals (gross)	.0	.0	0	0	0	0	0	0	.0
7. Reinsurance ceded	.0								
8. Totals (Net) (Page 3, Line 4)	0	0	0	0	0	0	0	0	0
9. Present value of amounts not yet due on claims	.0								
10. Reserve for future contingent benefits	.0								
11. Aggregate write-ins for other claim reserves	.0			0	.0	.0	0	0	.0
12. Totals (gross)	.0	.0	0	0	0	0	0	0	.0
13. Reinsurance ceded	.0								
14. Totals (Net) (Page 3, Line 7)	0	0	0	0	0	0	0	0	0
<b>DETAILS OF WRITE-INS</b>									
0501.									
0502.									
0503.									
0598. Summary of remaining write-ins for Line 5 from overflow page	.0	.0	0	.0	.0	0	0	0	.0
0599. Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0
1101.									
1102.									
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	.0	.0	0	.0	.0	0	0	0	.0
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0

NONE

(a) Includes \$ ..... premium deficiency reserve.

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**UNDERWRITING AND INVESTMENT EXHIBIT**

**PART 3 - ANALYSIS OF EXPENSES**

	Claim Adjustment Expenses		3 General Administrative Expenses	4 Investment Expenses	5 Total
	1 Cost Containment Expenses	2 Other Claim Adjustment Expenses			
1. Rent (\$ for occupancy of own building)			265,942		265,942
2. Salaries, wages and other benefits			2,845,194		2,845,194
3. Commissions (less \$ ceded plus \$ assumed)			16,175,508		16,175,508
4. Legal fees and expenses			1,084,279		1,084,279
5. Certifications and accreditation fees					0
6. Auditing, actuarial and other consulting services			428,167		428,167
7. Traveling expenses			11,471		11,471
8. Marketing and advertising			26,048		26,048
9. Postage, express and telephone			99,769		99,769
10. Printing and office supplies			0		0
11. Occupancy, depreciation and amortization					0
12. Equipment					0
13. Cost or depreciation of EDP equipment and software			187,200		187,200
14. Outsourced services including EDP, claims, and other services	3,775,693		1,266,835		5,042,528
15. Boards, bureaus and association fees			1,499,707		1,499,707
16. Insurance, except on real estate			32,882		32,882
17. Collection and bank service charges			1,594,331		1,594,331
18. Group service and administration fees					0
19. Reimbursements by uninsured plans					0
20. Reimbursements from fiscal intermediaries					0
21. Real estate expenses					0
22. Real estate taxes					0
23. Taxes, licenses and fees:					
23.1 State and local insurance taxes			85,041		85,041
23.2 State premium taxes			70,967		70,967
23.3 Regulatory authority licenses and fees			339,979		339,979
23.4 Payroll taxes			316,133		316,133
23.5 Other (excluding federal income and real estate taxes)			7,455,058		7,455,058
24. Investment expenses not included elsewhere				27,774	27,774
25. Aggregate write-ins for expenses	0	0	(778,066)	0	(778,066)
26. Total expenses incurred (Lines 1 to 25)	0	3,775,693	33,006,445	27,774	(a) 36,809,912
27. Less expenses unpaid December 31, current year		3,303,791	188,428		3,492,219
28. Add expenses unpaid December 31, prior year	0	2,448,357	675,822	0	3,124,179
29. Amounts receivable relating to uninsured plans, prior year	0	0	0	0	0
30. Amounts receivable relating to uninsured plans, current year					0
31. Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	0	2,920,259	33,493,839	27,774	36,441,872
<b>DETAILS OF WRITE-INS</b>					
2501. Fronting Fees				(778,066)	(778,066)
2502.					0
2503.					0
2598. Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
2599. Totals (Line 2501 through 2503 plus 2598) (Line 25 above)	0	0	(778,066)	0	(778,066)

(a) Includes management fees of \$ 3,859,509 to affiliates and \$ to non-affiliates.

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**EXHIBIT OF NET INVESTMENT INCOME**

	1 Collected During Year	2 Earned During Year
1. U.S. Government bonds .....	(a) 128,822	132,077
1.1 Bonds exempt from U.S. tax .....	(a) .....	.....
1.2 Other bonds (unaffiliated) .....	(a) .....	.....
1.3 Bonds of affiliates .....	(a) .....	.....
2.1 Preferred stocks (unaffiliated) .....	(b) .....	.....
2.11 Preferred stocks of affiliates .....	(b) .....	.....
2.2 Common stocks (unaffiliated) .....	(b) .....	.....
2.21 Common stocks of affiliates .....	(b) .....	.....
3. Mortgage loans .....	(c) .....	.....
4. Real estate .....	(d) .....	.....
5. Contract loans .....		
6. Cash, cash equivalents and short-term investments .....	(e) .95,204	.95,204
7. Derivative instruments .....	(f) .....	.....
8. Other invested assets .....		
9. Aggregate write-ins for investment income .....	0	0
10. Total gross investment income .....	224,026	227,281
11. Investment expenses .....		(g) 27,775
12. Investment taxes, licenses and fees, excluding federal income taxes .....		(g) .....
13. Interest expense .....		(h) .....
14. Depreciation on real estate and other invested assets .....		(i) .....
15. Aggregate write-ins for deductions from investment income .....		0
16. Total deductions (Lines 11 through 15) .....		27,775
17. Net investment income (Line 10 minus Line 16) .....		199,506
<b>DETAILS OF WRITE-INS</b>		
0901. .....		
0902. .....		
0903. .....		
0998. Summary of remaining write-ins for Line 9 from overflow page .....	0	0
0999. Totals (Lines 0901 through 0903 plus 0998) (Line 9 above) .....	0	0
1501. .....		
1502. .....		
1503. .....		
1598. Summary of remaining write-ins for Line 15 from overflow page .....		0
1599. Totals (Lines 1501 through 1503 plus 1598) (Line 15 above) .....		0

(a) Includes \$ ..... accrual of discount less \$ ..... 64,748 amortization of premium and less \$ ..... 2,568 paid for accrued interest on purchases.  
 (b) Includes \$ ..... accrual of discount less \$ ..... amortization of premium and less \$ ..... 0 paid for accrued dividends on purchases.  
 (c) Includes \$ ..... 0 accrual of discount less \$ ..... 0 amortization of premium and less \$ ..... paid for accrued interest on purchases.  
 (d) Includes \$ ..... for company's occupancy of its own buildings; and excludes \$ ..... interest on encumbrances.  
 (e) Includes \$ ..... accrual of discount less \$ ..... amortization of premium and less \$ ..... paid for accrued interest on purchases.  
 (f) Includes \$ ..... accrual of discount less \$ ..... amortization of premium.  
 (g) Includes \$ ..... investment expenses and \$ ..... investment taxes, licenses and fees, excluding federal income taxes, attributable to segregated and Separate Accounts.  
 (h) Includes \$ ..... interest on surplus notes and \$ ..... interest on capital notes.  
 (i) Includes \$ ..... depreciation on real estate and \$ ..... depreciation on other invested assets.

**EXHIBIT OF CAPITAL GAINS (LOSSES)**

	1 Realized Gain (Loss) On Sales or Maturity	2 Other Realized Adjustments	3 Total Realized Capital Gain (Loss) (Columns 1 + 2)	4 Change in Unrealized Capital Gain (Loss)	5 Change in Unrealized Foreign Exchange Capital Gain (Loss)
1. U.S. Government bonds .....			.0		
1.1 Bonds exempt from U.S. tax .....			.0		
1.2 Other bonds (unaffiliated) .....			.0		
1.3 Bonds of affiliates .....	0	0	.0	0	0
2.1 Preferred stocks (unaffiliated) .....	0	0	.0	0	0
2.11 Preferred stocks of affiliates .....	0	0	.0	0	0
2.2 Common stocks (unaffiliated) .....	0	0	.0	0	0
2.21 Common stocks of affiliates .....	0	0	.0	0	0
3. Mortgage loans .....	0	0	.0	0	0
4. Real estate .....	0	0	.0	0	0
5. Contract loans .....					
6. Cash, cash equivalents and short-term investments .....			.0	0	0
7. Derivative instruments .....			.0	0	0
8. Other invested assets .....	0	0	.0	0	0
9. Aggregate write-ins for capital gains (losses) .....	0	0	.0	0	0
10. Total capital gains (losses) .....	0	0	.0	0	0
<b>DETAILS OF WRITE-INS</b>					
0901. .....			0		
0902. .....			0		
0903. .....			0		
0998. Summary of remaining write-ins for Line 9 from overflow page .....	0	0	0	0	0
0999. Totals (Lines 0901 through 0903 plus 0998) (Line 9 above) .....	0	0	0	0	0

**NONE**

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**EXHIBIT OF NONADMITTED ASSETS**

	1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1. Bonds (Schedule D).....	0	0	0
2. Stocks (Schedule D):			
2.1 Preferred stocks .....	0	0	0
2.2 Common stocks .....	0	0	0
3. Mortgage loans on real estate (Schedule B):			
3.1 First liens .....	0	0	0
3.2 Other than first liens .....	0	0	0
4. Real estate (Schedule A):			
4.1 Properties occupied by the company .....	0	0	0
4.2 Properties held for the production of income.....	0	0	0
4.3 Properties held for sale .....	0	0	0
5. Cash (Schedule E-Part 1), cash equivalents (Schedule E-Part 2) and short-term investments (Schedule DA).....	0	0	0
6. Contract loans .....	0	0	0
7. Derivatives (Schedule DB).....	0	0	0
8. Other invested assets (Schedule BA) .....	0	0	0
9. Receivables for securities .....	0	0	0
10. Securities lending reinvested collateral assets (Schedule DL).....	0	0	0
11. Aggregate write-ins for invested assets .....	0	0	0
12. Subtotals, cash and invested assets (Lines 1 to 11) .....	0	0	0
13. Title plants (for Title insurers only).....	0	0	0
14. Investment income due and accrued .....	0	0	0
15. Premiums and considerations:			
15.1 Uncollected premiums and agents' balances in the course of collection.....	0	0	0
15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due.....	0	0	0
15.3 Accrued retrospective premiums and contracts subject to redetermination .....	0	0	0
16. Reinsurance:			
16.1 Amounts recoverable from reinsurers .....	0	0	0
16.2 Funds held by or deposited with reinsured companies .....	0	0	0
16.3 Other amounts receivable under reinsurance contracts .....	5,345,247	4,999,221	(346,026)
17. Amounts receivable relating to uninsured plans .....	0	0	0
18.1 Current federal and foreign income tax recoverable and interest thereon .....	0	0	0
18.2 Net deferred tax asset.....	0	0	0
19. Guaranty funds receivable or on deposit .....	0	0	0
20. Electronic data processing equipment and software.....	0	0	0
21. Furniture and equipment, including health care delivery assets.....	0	0	0
22. Net adjustment in assets and liabilities due to foreign exchange rates .....	0	0	0
23. Receivables from parent, subsidiaries and affiliates .....	0	0	0
24. Health care and other amounts receivable.....	0	0	0
25. Aggregate write-ins for other-than-invested assets .....	476,988	393,397	(83,591)
26. Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25).....	5,822,235	5,392,618	(429,617)
27. From Separate Accounts, Segregated Accounts and Protected Cell Accounts.....	0	0	0
28. Total (Lines 26 and 27).....	5,822,235	5,392,618	(429,617)
<b>DETAILS OF WRITE-INS</b>			
1101. ....	0	0	0
1102. ....	0	0	0
1103. ....	0	0	0
1198. Summary of remaining write-ins for Line 11 from overflow page .....	0	0	0
1199. Totals (Lines 1101 through 1103 plus 1198) (Line 11 above) .....	0	0	0
2501. Prepaid Expenses.....	476,988	393,397	(83,591)
2502. ....	0	0	0
2503. ....	0	0	0
2598. Summary of remaining write-ins for Line 25 from overflow page .....	0	0	0
2599. Totals (Lines 2501 through 2503 plus 2598) (Line 25 above) .....	476,988	393,397	(83,591)

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY**

Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	6 Current Year Member Months
						Total Members at End of
1. Health Maintenance Organizations.....	0					
2. Provider Service Organizations.....	0					
3. Preferred Provider Organizations.....	0					
4. Point of Service.....	0					
5. Indemnity Only.....	0					
6. Aggregate write-ins for other lines of business.....	721,781	871,827	903,088	928,800	958,026	10,909,167
7. Total	721,781	871,827	903,088	928,800	958,026	10,909,167
<b>DETAILS OF WRITE-INS</b>						
0601. Medicare Part D Prescription Drug Plan.....	704,966	860,571	896,226	923,759	957,547	10,805,199
0602. Commercial Prescription Drug Plan.....	16,815	11,256	6,862	5,041	479	103,968
0603.....	0					
0698. Summary of remaining write-ins for Line 6 from overflow page.....	0	0	0	0	0	0
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)	721,781	871,827	903,088	928,800	958,026	10,909,167

# ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company

## NOTES TO FINANCIAL STATEMENTS

### 1. Summary of Significant Accounting Policies

#### A. Accounting Practices

The financial statements of Elixir Insurance Company (Company) are presented on the basis of accounting practices prescribed or permitted by the Ohio Department of Insurance (ODI).

The ODI recognizes only statutory accounting practices prescribed or permitted by the state of Ohio for determining and reporting the financial condition and results of operations of an insurance company and for determining its solvency under the Ohio Insurance Law. The National Association of Insurance Commissioners' (NAIC) Accounting Practices and Procedures Manual, (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the state of Ohio. There is no deviation from the NAIC Accounting Practices and Procedures Manual.

	<u>SSAP#</u>	<u>F/S Page</u>	<u>F/S Line #</u>	<u>2020</u>	<u>2019</u>
<b><u>NET INCOME</u></b>					
Elixir Insurance Company, state basis (Page 4, Line 32, Column 2 & 3)				\$(24,651,395)	\$6,257,092
State Prescribed Practices that are an increase/(decrease) from NAIC SAP				\$0	\$0
State Permitted Practices that are an increase/(decrease) from NAIC SAP				\$0	\$0
NAIC SAP				<u>\$(24,651,395)</u>	<u>\$6,257,092</u>
<b><u>SURPLUS</u></b>					
Elixir Insurance Company, state basis (Page 3, Line 33, Column 3 & 4)				\$74,940,591	\$54,781,897
State Prescribed Practices that are an increase/(decrease) from NAIC SAP				\$0	\$0
State Permitted Practices that are an increase/(decrease) from NAIC SAP				\$0	\$0
NAIC SAP				<u>\$74,940,591</u>	<u>\$54,781,897</u>

#### B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with the Annual Statement Instruction and Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Such estimates and assumptions could change in the future as more information becomes known, which could impact amount reported and disclosed herein. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period.

#### C. Accounting Policy

The Company receives premium for plans offered under Medicare Part D. Premiums are earned on a monthly basis over the terms of the contract. There are 5 sources of Premium as follows:

- 1) Part D Subsidy – The amount of Premium remitted by Medicare for each individual that is enrolled in a plan (“Insured”).
- 2) Basic Member Premium - The amount of Premium remitted by the individual Insured.
- 3) Low Income Premium Subsidy - The amount of Basic Member Premium remitted by Medicare for each Insured eligible for Low Income Subsidies (“LIS”). This amount is paid on behalf of the Insured for their Premium.
- 4) Risk Corridor Adjustment – The calculated Premium adjustment for losses that exceed the target profit thresholds that are set in the Company’s annual Medicare Part D bids.
- 5) Supplemental Member Premium – Premium an Insured pays for enhanced benefit coverage and/or non-Medicare covered drugs.

Expenses incurred in connection with acquiring new business and retaining existing business are charged to operations as incurred.

In addition, the Company abides by the following policies:

- 1) Short-term investments are stated at amortized cost.
- 2) Bonds are stated at amortized cost. Amortization of the bond premium or discount is calculated using the scientific (constant yield) interest method taking into consideration specified interest and premium provisions over the life of the bonds.
- 3) The Company has no investments in common stocks.
- 4) The Company has no preferred stocks.

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company  
NOTES TO FINANCIAL STATEMENTS**

- 5) The Company has no mortgage loans.
- 6) The Company has no loan-backed securities.
- 7) The Company has no investments in subsidiaries, controlled or affiliated entities.
- 8) The Company has no investments in joint ventures, partnerships or limited liability companies
- 9) The Company has no derivatives.
- 10) The Company had no premium deficiency calculation.
- 11) The Company's claims primarily consist of prescription drug claims processed at the point of sale with the pharmacy. Loss liabilities are primarily based on claims and claims adjustments expenses processed, but unpaid to the pharmacy benefit manager. The Company has established an incurred but not reported reserve. That is based on historical rates of negative claims development experience.
- 12) The Company does not have a capitalization policy.
- 13) The Company does not have pharmaceutical rebate receivables.

**2. Accounting Changes and Corrections of Errors**

None.

**3. Business Combination and Goodwill**

- A. Statutory Purchase Method - Not Applicable
- B. Statutory Merger - Not Applicable
- C. Assumption Reinsurance - Not Applicable
- D. Impairment Loss - Not Applicable

**4. Discontinued Operations**

The Company had no operations that were discontinued during 2020 or 2019.

**5. Investments**

- A. Mortgage Loans, including Mezzanine Real Estate Loans

The Company did not have investments in mortgage loans at December 31, 2020 or 2019.

- B. Debt Restructuring

The Company did not have invested assets that were restructured debt at December 31, 2020 or 2019.

- C. Reverse Mortgages

The Company did not have investments in reverse mortgages at December 31, 2020 or 2019.

- D. Loan-Backed Securities

The Company did not have loan-backed securities at December 31, 2020 or 2019.

- E. Dollar Repurchase Agreements and/or Securities Lending Transactions

The Company did not enter into repurchase agreements or securities lending transactions at December 31, 2020 or 2019.

- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not have any repurchase agreements transactions accounted for as secured borrowing for the year ended December 31, 2020 or 2019.

- G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not have any reverse repurchase agreements transactions accounted for as secured borrowing for the year ended December 31, 2020 or 2019.

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**  
**NOTES TO FINANCIAL STATEMENTS**

**H. Repurchase Agreements Transactions Accounted for as a Sale**

The Company did not have any repurchase agreements transactions accounted for as a sale for the year ended December 31, 2020 or 2019.

**I. Reverse Repurchase Agreements Transactions Accounted for as a Sale**

The Company did not have any reverse repurchase agreements transactions accounted for as a sale for the year ended December 31, 2020 or 2019.

**J. Real Estate**

The Company did not have any reportable real estate transactions for the year ended December 31, 2020 or 2019.

**K. Low-Income Housing Tax Credits (LIHTC)**

The Company did not have any investments in LIHTC at December 31, 2020 or 2019.

**L. Restricted Assets**

**(1) Restricted Assets (Including Pledged)**

**December 31, 2020**

		1	2	3	4	5	6	7
	Restricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Percentage Gross Restricted to Total Assets	Percentage Admitted Restricted to Total Admitted Assets
a.	Subject to contractual obligation for which liability is not shown							
b.	Collateral held under security lending agreements							
c.	Subject to repurchase agreements							
d.	Subject to reverse repurchase agreements							
e.	Subject to dollar repurchase agreements							
f.	Subject to dollar reverse repurchase agreements							
g.	Place under option contracts							
h.	Letter stock or securities restricted as to sale - excluding FHLB capital stock							
i.	FHLB capital stock							
j.	On deposit with states	4,931,941	4,941,191	(9,250)	-	4,931,941	0.9%	0.9%
k.	On deposit with other regulatory bodies							
l.	Pledged as collateral to FHLB (Including assets backing funding agreements)							
m.	Pledged as collateral not captured in other categories							
n.	Other restricted assets							
o.	Total Restricted Assets	4,931,941	4,941,191	(9,250)	-	4,941,191	0.9%	0.9%

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**  
**NOTES TO FINANCIAL STATEMENTS**

**December 31, 2019**

		1	2	3	4	5	6	7
Restricted Asset Category		Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Percentage Gross Restricted to Total Assets	Percentage Admitted Restricted to Total Admitted Assets
a.	Subject to contractual obligation for which liability is not shown							
b.	Collateral held under security lending agreements							
c.	Subject to repurchase agreements							
d.	Subject to reverse repurchase agreements							
e.	Subject to dollar repurchase agreements							
f.	Subject to dollar reverse repurchase agreements							
g.	Place under option contracts							
h.	Letter stock or securities restricted as to sale - excluding FHLB capital stock							
i.	FHLB capital stock							
j.	On deposit with states	4,941,191	5,154,955	(213,764)	-	4,941,191	0.7%	0.7%
k.	On deposit with other regulatory bodies							
l.	Pledged as collateral to FHLB (Including assets backing funding agreements)							
m.	Pledged as collateral not captured in other categories							
n.	Other restricted assets							
o.	Total Restricted Assets	4,941,191	5,154,955	(213,764)	-	4,941,191	0.7%	0.7%

**M. Working Capital Finance Investments**

The Company did not have any working capital finance investments for the year ended December 31, 2020 or 2019.

**N. Offsetting and Netting of Assets and Liabilities**

The Company did not have any offsetting and netting of assets and liabilities for the year ended December 31, 2020 or 2019.

**O. Structured Notes**

The Company did not have any structured notes for the year ended December 31, 2020 or 2019.

**P. 5\* Securities**

The Company did not have any 5\* securities for the year ended December 31, 2020 or 2019.

**Q. Short Sales**

The Company did not have any short sales for the year ended December 31, 2020 or 2019.

**R. Prepayment Penalty and Acceleration Fees**

The Company did not have any prepayment penalty and acceleration fees for the year ended December 31, 2020 or 2019.

# **ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company NOTES TO FINANCIAL STATEMENTS**

## 6. Joint Ventures, Partnerships and Limited Liability Companies

- A. The Company did not have investments in Joint Ventures, Partnerships or Limited Liability Companies that exceeded 10% of its admitted assets at December 31, 2020 or 2019.
- B. Not applicable to the Company.

## 7. Investment Income

- A. The Company had no due and accrued investment income with amounts that are over 90 days past due.
- B. At December 31, 2020 and 2019 there was no non-admitted accrued investment interest income.

## 8. Derivative Instruments

The Company has no derivative instruments at December 31, 2020 or 2019.

## 9. Income Taxes

A. The components of the net deferred tax asset/(liability) at December 31 are as follows:

	12/31/2020			12/31/2019			Change		
	(1) Ordinary	(2) Capital	(3) (Col 1+2) Total	(1) Ordinary	(2) Capital	(3) (Col 1+2) Total	(7) (Col 1-4) Ordinary	(8) (Col 2-5) Capital	(9) (Col 7+8) Total
(a)	(a) Gross Deferred Tax Assets	\$ 3,840,497	\$ 3,840,497	\$ 281,791	\$ -	\$ 281,791	\$ 3,558,706	\$ -	\$ 3,558,706
(b)	(b) Statutory Valuation Allowance Adjustments	819,000	-	819,000	-	-	819,000	-	819,000
(c)	(c) Adjusted Gross Deferred Tax Assets								
(d)	(d) Deferred Tax Assets Nonadmitted	3,021,497	-	3,021,497	281,791	-	281,791	2,739,706	-
(e)	(e) Subtotal Net Admitted Deferred Tax Asset	-	-	-	-	-	-	-	-
(f)	(f) Deferred Tax Liabilities	3,021,497	-	3,021,497	281,791	-	281,791	2,739,706	-
(g)	(g) Net Admitted Deferred Tax Asset/ (Net Deferred Tax Liability) (1e - 1f)	-	-	-	-	-	-	-	-
		\$ 3,021,497	\$ -	\$ 3,021,497	\$ 281,791	\$ -	\$ 281,791	\$ 2,739,706	\$ -
2.	12/31/2020			12/31/2019			Change		
	(1) Ordinary	(2) Capital	(3) (Col 1+2) Total	(1) Ordinary	(2) Capital	(3) (Col 1+2) Total	(7) (Col 1-4) Ordinary	(8) (Col 2-5) Capital	(9) (Col 7+8) Total
Admission Calculation Components									
SSAP No. 101									
(a)	(a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
(b)	(b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation (The Lesser of 2(b)1 and 2(b)2 Below)	\$ 3,021,497	-	\$ 3,021,497	\$ 281,791	-	\$ 281,791	\$ 2,739,706	\$ -
1.	1. Adjusted Gross Deferred Tax Assets Expected to be Realized Following the Balance Sheet Date	\$ 3,021,497	-	\$ 3,021,497	\$ 281,791	-	\$ 281,791	\$ 2,739,706	\$ -
2.	2. Adjusted Gross Deferred Tax Assets Allowed Per Limitation Threshold	XXX	XXX	\$ -	XXX	XXX	\$ -	XXX	XXX
(c)	(c) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) Offset by Gross Deferred Tax Liabilities	\$ -	-	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -
(d)	(d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101	Total (2(a) + 2(b) + 2(c))	\$ 3,021,497	\$ -	\$ 3,021,497	\$ 281,791	\$ -	\$ 281,791	\$ 2,739,706

	2020	2019
(a) Ratio Percentage Used to Determine Recovery Period and Threshold Limitation Amount	435%	433%
(b) Amount of Adjusted Capital and Surplus Used to Determine Recovery Period and Threshold Limitation in 2(b)2 Above	\$ 74,940,591	\$ 54,781,897

B. There are no deferred tax liabilities that are not recognized at December 31, 2020 and 2019.

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**  
**NOTES TO FINANCIAL STATEMENTS**

C. Current income taxes incurred consist of the following major components:

	(1) 12/31/2020	(2) 12/31/2019	(3) (Col 1-2) Change
1. Current Income Tax			
(a) Federal	\$ -	\$ 1,764,234	\$ (1,764,234)
(b) Foreign	-	-	-
(c) Subtotal	-	1,764,234	(1,764,234)
(d) Federal income tax on net capital gains	-	-	-
(e) Utilization of capital loss carryforwards	-	-	-
(f) Other	-	-	-
(g) Federal and foreign income taxes incurred	-	-	-
	<b>\$ -</b>	<b>\$ 1,764,234</b>	<b>\$ (1,764,234)</b>
2. Deferred Tax Assets:			
(a) Ordinary			
(1) Discounting of unpaid losses	\$ -	\$ -	\$ -
(2) Unearned premium reserve	-	-	-
(3) Policyholder reserves	-	-	-
(4) Investments	-	-	-
(5) Deferred acquisition costs	-	-	-
(6) Policyholder dividends accrual	-	-	-
(7) Fixed Assets	-	-	-
(8) Compensation and benefits accrual	-	-	-
(9) Pension accrual	-	-	-
(10) Receivables - nonadmitted	721,570	281,791	439,779
(11) Net operating loss carry-forward	3,118,927	-	3,118,927
(12) Tax credit carryforward	-	-	-
(13) Other (including items <5% of total ordinary tax assets)	-	-	-
	<b>(99) Subtotal</b>	<b>\$ 3,840,497</b>	<b>\$ 281,791</b>
		<b>\$ 3,558,706</b>	
(b) Statutory valuation allowance adjustments	819,000	-	819,000
(c) Nonadmitted	-	-	-
(d) Admitted ordinary deferred tax assets (2(a)(99) - 2(b) -2(c))	3,021,497	281,791	2,739,706
(e - h) Admitted capital deferred tax assets	-	-	-
(i) Admitted deferred tax assets (2(d) + 2(h))	<b>\$ 3,021,497</b>	<b>\$ 281,791</b>	<b>\$ 2,739,706</b>
3. Deferred Tax Liabilities:			
(a) Ordinary			
(1) Investments	\$ -	\$ -	\$ -
(2) Fixed Assets	-	-	-
(3) Deferred and uncollected premium	-	-	-
(4) Policyholder reserves	-	-	-
(5) Other (including items <5% of total ordinary tax assets)	-	-	-
	<b>(99) Subtotal</b>	<b>\$ -</b>	<b>\$ -</b>
		<b>\$ -</b>	
(b) Capital	-	-	-
(c) Deferred tax liabilities	<b>\$ -</b>	<b>\$ -</b>	<b>\$ -</b>
4. Net deferred tax assets/liabilities (2(i) + 3(c))	<b>\$ 3,021,497</b>	<b>\$ 281,791</b>	<b>\$ 2,739,706</b>

D. Reconciliation of Federal Income Tax Rate to Actual Effective Rate for 2020:

**2020**

	<u>Amount</u>	<u>Effective Tax Rate (%)</u>
Provision at the statutory rate	\$ (5,176,793)	21.0
Annual fee on health insurance providers	1,616,976	(6.6)
Net operating loss carryforward	3,118,927	(12.7)
Other tax differences	<b>440,890</b>	<b>(1.9)</b>
Federal and foreign income taxes incurred	<b>\$ 0</b>	<b>-</b>
		0.0%

E. The Company has operating losses of \$14.9 million available for offsetting net taxable income. The Company has established a reserve of \$3.9 million for amounts that may not be realizable in future periods.

# ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company

## NOTES TO FINANCIAL STATEMENTS

- F. The Company's tax return will be consolidated with that of Rite Aid Corporation and subsidiaries. The Company has a written tax sharing agreement with the Parent, and its allocation of the Parent's federal income and state income and premium tax liability is based on the Company's federal tax liability determined as if the Company were filing its own separate tax return each year. The Company's tax sharing agreement with the Parent provides that the Company will pay the Parent for its net operating losses to the extent that such net operating loss is used in the reduction of the Company's federal income tax liability.

- G. Not applicable.

### 10. Information Concerning Parent, Subsidiaries and Affiliates

- A. Nature of the relationship

Elixir Insurance Company is a wholly-owned subsidiary of Envision Pharmaceutical Holdings LLC. ("EPH"). Elixir Rx Options, LLC ("ROI") and First Florida Insurers of Tampa, LLC ("FFI") are affiliates of EIC and wholly-owned subsidiaries of EPH.

- B. Transactions for each Period

The Company received capital contributions from EPHI of \$7.5 million and \$35.0 million in September 2020 and December 2020, respectively, to meet minimum statutory capital and surplus requirements.

In February 2020, the Company used the proceeds from the sale of its 2019 CMS Medicare Part D receivables (See Note 17A.) to pay ROI for claims and other amounts outstanding for pharmacy benefit management services. According to the terms of the PBMSA with ROI, the Company was provided with an early payment discount in the amount of \$16.9 million. Additionally, the Company completed an exchange with ROI of an early payment discount applicable to payment of outstanding claims for the deferred purchase price receivable of \$36.4 million received from the sale of its 2019 CMS Medicare Part D receivables.

In November 2020, the Company used the proceeds from the sale of its 2020 CMS Medicare Part D receivables as of September 30, 2020 (See Note 17A.) to pay ROI for claims and other amounts outstanding for pharmacy benefit management services. According to the terms of the PBMSA with ROI, the Company was provided with an early payment discount in the amount of \$19.2 million. Additionally, the Company completed an exchange with ROI of an early payment discount applicable to payment of outstanding claims for the deferred purchase price receivable of \$34.9 million received from the sale of its 2020 CMS Medicare Part D receivables.

The Company has a pharmacy benefit management services agreement ("PBMSA") with ROI. The transactions under the agreement totaled \$2,789,635,759 and \$1,731,063,001 for the years ended December 31, 2020 and 2019, respectively.

The Company has a general insurance agency agreement with FFI. The Company incurred \$355,516 and \$386,633 in commissions to FFI for the years ended December 31, 2020 and 2019, respectively.

- C. The Company did not have any transactions with related parties who are not reported on Schedule Y for the years ended December 31, 2020 and 2019, respectively.

- D. Amounts Due to or from Related Parties

At December 31, 2020 and December 31, 2019, the Company reported \$325,174,224 and \$445,095,143 due to affiliates, respectively. Additionally, the amounts reported as unpaid claims and unpaid claims adjustment expenses are due to ROI under the PBMSA in the amounts of \$126,901,119 and \$3,303,791 as of December 31, 2020 and \$175,729,367 and \$2,448,357 as of December 31, 2019. The December 31, 2020 payable balances represent intercompany transactions that will be settled in accordance with the settlement terms of the PBMSA.

- E. Management, Service Contracts, Cost Sharing Arrangements

Under the PBMSA, ROI has agreed to provide certain management services to the Company. These designated services include but are not limited to payroll, claims processing, facilities, customer service and other general administrative services. The PBMSA with ROI was extended to December 31, 2021.

The Company has a written tax sharing agreement with the Parent, and its allocation of the Parent's federal income and state income and premium tax liability is based on the Company's federal tax liability determined as if the Company were filing its own separate tax return each year. The Company's tax sharing agreement with the Parent provides that the Company will pay the Parent for its net operating losses to the extent that such net operating loss is used in the reduction of the Company's federal income tax liability. Furthermore, state income and premium tax that results from a combined/consolidated filing shall be allocated to each entity based on the aggregate apportionment of all participating members included within the respective filing. Intercompany tax balances are settled annually.

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company  
NOTES TO FINANCIAL STATEMENTS**

F. The Company did not enter into guarantees or undertaking for the benefit of an affiliate which would result in a material contingent exposure of the Company's or any affiliated insurer's assets or liabilities.

G. Nature of Relationships that Could Affect Operations  
All outstanding shares of the Company are owned by EPH.

H. Amount Deducted for Investment in Upstream Company  
None

I. Detail of Investments in Subsidiaries, Controlled or Affiliated Companies Greater than 10% of Admitted Assets  
None

J. Write-down for Impairments of Investments in Subsidiaries, Controlled or Affiliated Companies  
None

K. Investment in a Foreign Insurance Subsidiary  
None

L. Investment in Downstream Noninsurance Holding Company  
None

M. All Investments in Subsidiaries, Controlled or Affiliated Companies  
None

N. Investments in Insurance Subsidiaries, Controlled or Affiliated Companies  
None

O. Subsidiaries, Controlled or Affiliated Companies Loss Tracking  
None

**11. Debt**

The Company has no debt outstanding at December 31, 2020 and 2019.

**12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans.**

Not applicable to the Company.

**13. Capital and Surplus, Dividend Restrictions and Quasi-Reorganizations**

A. Outstanding Shares

As of December 31, 2020, the Company has 20,000 shares of \$100 par value common stock authorized, issued and outstanding.

B. Preferred Stock

The Company has no preferred stock outstanding.

C. Dividend Restriction

The Company is generally restricted by insurance laws of the State of Ohio with regard to amounts that can be transferred to the Parent in the form of dividends without the approval of the ODI.

D. Dividends Paid

No dividends were paid by the Company during the years ending December 31, 2020 or 2019.

E. Profits Payable as Dividends

The Company is restricted with regard to amounts that can be transferred to the Parent in the form of dividends, loans, or advances without the approval of the ODI to the greater of (a) 10 percent of statutory surplus as of December 31 of the year preceding the dividend, loan or advancement or (b) 100 percent of statutory net income for the year ended December 31 preceding the dividend, loan or advancement.

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company  
NOTES TO FINANCIAL STATEMENTS**

**F. Unassigned Surplus Restriction**

Unassigned surplus funds are not restricted at December 31, 2020 or 2019.

**G. Mutual Surplus Advances**

There have been no advances to surplus at December 31, 2020.

**H. Company Stock Held for Special Purpose**

There are no shares of stock held for special purposes at December 31, 2020.

**I. Changes in Special Surplus Funds**

The Company had special surplus of \$0 and \$7.67 million as of December 31, 2020 and 2019, respectively. The change in the balance of special surplus funds from the prior year is due to changes in the amount of the ACA Section 9010 Health Insurers Fee.

**J. Changes in Unassigned Funds**

The Company has no cumulative unrealized capital gains and losses included in unassigned funds.

**K. Surplus Notes**

The company has no surplus notes.

**L. Reinstatement due to Prior Quasi-Reorganizations**

The Company had no restatements due to prior quasi-reorganizations.

**M. Quasi-Reorganizations over Prior 10 Years**

The Company has not been involved in quasi-reorganization during the past 10 years.

**14. Liabilities, Contingencies and Assessments**

**A. Contingent Commitments**

The Company has no contingent commitments at December 31, 2020.

**B. Assessments**

The Company has not recorded a liability for an assessment as of December 31, 2020.

**C. Gain Contingencies**

The Company has no gain contingencies at December 31, 2020.

**D. Claims-Related Extra Contractual Obligation and Bad Faith Losses Stemming from Lawsuits**

Not Applicable to the Company.

**E. Joint and Several Liabilities**

Not Applicable to the Company

**F. All Other Contingencies**

Under the terms of a reinsurance agreement for a prior plan year, the Company billed and, in March 2018, issued a demand for payment to a reinsurer for \$1.2 million due to the Company for the final settlement of the CMS Part D plan year for 2012. The reinsurer refused payment and in April 2018, the Company issued a request for arbitration as allowed by the reinsurance agreement in order to collect the monies owed. The Company billed and, in May 2019, issued a demand for payment to the reinsurer for \$3.8 million due to the Company for the final settlement of the CMS Part D plan year for 2013. The Company billed and, in May 2020 issued a demand for payment to the reinsurer for \$245K due to the Company for the final settlement of the CMS Part D plan year for 2014. The reinsurer has refused payment for both 2013 and 2014 and the amounts have been included in the open arbitration proceedings. The arbitration proceedings commenced in 2019 and remain in progress.

The Company asserts that the \$5.3 million due from the reinsurer is valid and collectible. However, the \$5.3 million has been recorded as a non-admitted asset at December 31, 2020 in accordance with statutory accounting principles.

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company  
NOTES TO FINANCIAL STATEMENTS**

**15. Leases**

**A. Lessee Leasing Arrangements**

The Company has not entered into any lessee leasing arrangements.

The Company has not entered into any sale and leaseback arrangements.

**B. Lessor Leasing Arrangements**

The Company has not entered into any operating or leveraged leases.

**16. Information about Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit Risk**

The Company has no financial instruments with off-balance sheet risk and concentration of credit risk.

**17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities**

**A. Transfers of Receivables Reported as Sales**

In February 2020, the Company sold its 2019 Plan Year Medicare Part D Risk Corridor, Low Income Cost Sharing Subsidies, and Catastrophic Reinsurance Subsidies receivables of \$501.4 million without recourse to an investor. The Company realized a loss of as a result of the sale of \$16.9 million.

In November 2020, the Company sold its 2020 Plan Year Medicare Part D Risk Corridor, Low Income Cost Sharing Subsidies, and Catastrophic Reinsurance Subsidies receivables as of September 30, 2020 of \$464.0 million without recourse to an investor. The Company realized a loss of as a result of the sale of \$19.2 million.

**B. Transfer and Servicing of Financial Assets**

Not applicable to the Company.

**C. Wash Sales**

Not applicable to the Company.

**18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans**

**A. Administrative Services Only (ASO) Plans**

**December 31, 2020**

	ASO Uninsured Plans	Uninsured Portion of Partially Insured Plans	Total ASO
a. Net reimbursement for administrative expenses (including administrative fees in excess of actual expenses)	\$351,750	\$0	\$351,750
b. Total net other income or expenses (including interest paid to or received from plans)	\$0	\$0	\$0
c. Net gain or loss from operations	\$351,750	\$0	\$351,750
d. Total claim payment volume	234,425	N/A	234,425

**December 31, 2019**

	ASO Uninsured Plans	Uninsured Portion of Partially Insured Plans	Total ASO
a. Net reimbursement for administrative expenses (including administrative fees in excess of actual expenses)	\$379,552	\$0	\$379,552
b. Total net other income or expenses (including interest paid to or received from plans)	\$0	\$0	\$0
c. Net gain or loss from operations	\$379,552	\$0	\$379,552
d. Total claim payment volume	287,915	N/A	287,915

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**  
**NOTES TO FINANCIAL STATEMENTS**

- B. Administrative Services Contract (ASC) Plans  
Not applicable to the Company.
- C. Medicare or Other Similarly Structured Cost Based Reimbursement Contracts  
Not applicable to the Company.

**19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators**

Name/Address of MGA	FEIN Number	Exclusive Contract	Type of Business Written	Types of Authority Granted	2020 Total Direct Premiums Written	2019 Total Direct Premiums Written
PRAM Insurance Services, Inc. 1 Pointe Drive Brea, CA 92821	33-0367265	Yes	Commercial Group Prescription Drug Plans	C, CA, B, P, U	\$1,082,518	\$2,647,770

**20. Fair Value Measurements**

The Company has no assets recorded at fair value as of December 31, 2020 or 2019.

**21. Other Items**

- A. Unusual or Infrequent Items  
Not applicable to the Company.
- B. Troubled Debt Restructuring for Debtors  
Not applicable to the Company.
- C. Other Disclosures

Company Name Change

Effective June 1, 2020, the name of the company was changed to Elixir Insurance Company from Envision Insurance Company. The name change is the result of a corporate rebranding initiative and had no change in the operations or products provided by the Company.

COVID-19 Pandemic

In 2020, the U.S. and global economies have been adversely impacted by a pandemic outbreak of the COVID-19 virus which has disrupted many businesses, including majority of states implementing restrictions on operations. The Company incurred additional claims expense from utilization due to removal of refill too soon limits on Medicare Part D insureds which may have negatively affected financial results in 2020. It is not possible to estimate the direct impact of this change. Additionally, uncertainty exists as to how this may impact the Company's operations in future periods.

- D. Business Interruption Insurance Recoveries  
Not applicable to the Company.
- E. State Transferable Tax Credits  
Not applicable to the Company.
- F. Subprime-Mortgage-Related Risk Exposure  
Not applicable to the Company.
- G. Retained Assets  
Not applicable to the Company.
- H. Insurance Linked Securities  
Not applicable to the Company.
- I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy  
Not applicable to the Company.

# ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company

## NOTES TO FINANCIAL STATEMENTS

### 22. Events Subsequent

The Company used February 21, 2021, the date these statutory financial statements were available to be issued as the date through which subsequent events have been evaluated for disclosure.

#### Type I – Recognized Subsequent Events:

No items were discovered that require disclosure.

#### Type II – Nonrecognized Subsequent Events:

##### Asset Sale

In February 2021, the Company sold its 2020 Plan Year Medicare Part D Risk Corridor, Low Income Cost Sharing Subsidies, and Catastrophic Reinsurance Subsidies receivables as of December 31, 2020 of \$300.0 million without recourse to an investor. The Company realized a loss as a result of the sale. The Company used the proceeds from the sale to pay ROI for claims and other amounts outstanding for pharmacy benefit management services. The loss above was offset by a gain recognized from an early payment discount taken on the amounts paid to ROI which was equal to the loss. The early payment discount was taken according to the terms of the PBMSA with ROI.

##### ACA 9010 Fee

Effective January 1, 2014, the Company was subject to an annual fee under section 9010 of the Federal Affordable Care Act (“ACA”). This annual fee is allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of health insurance for any U.S. health risk that is written during the preceding calendar year. A health insurance entity's portion of the annual fee becomes payable once the entity provides health insurance for a U.S. health risk for each calendar year beginning on or after January 1 of the year the fee is due.

As of January 1, 2020, the Company had written health insurance subject to the annual Health Insurance Providers fee under section 9010 of the Federal Affordable Care Act (“ACA”). The Company's portion of the fee is \$7.5 million and is reported in these statements as General Administrative Expenses at December 31, 2020. The 2020 fee is eligible for ceding under certain reinsurance agreements and is reported net of reinsurance recovery.

The Further Consolidated Appropriations Act, 2020, Division N, Subtitle E § 502 has repealed the annual fee on health insurance providers for calendar years beginning after December 31, 2020. As such, no amount has been accrued as Special Surplus in 2020 because no fee will be due in calendar 2021 or thereafter.

		Current Year	Prior Year
A.	Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the federal Affordable Care Act (YES/NO)?	YES	YES
B.	ACA fee assessment payable for the upcoming year	\$0	\$7,669,803
C.	ACA fee assessment paid	\$ 7,699,884	\$0
D.	Premium written subject to ACA 9010 assessment	\$0	\$405,308,620
E.	Total Adjusted Capital before surplus adjustment (Five Year Historical Line 14)	\$74,940,591	\$54,781,897
F.	Total Adjusted Capital after surplus adjustment (Five Year Historical Line 14 minus 22B above)	\$74,940,591	\$47,112,094
G.	Authorized control level after surplus adjustment	\$17,225,913	\$12,588,441
H.	Would reporting the ACA assessment as of December 31, 2020 and 2019 have triggered an RBC action level (YES/NO)?	NO	NO

### 23. Reinsurance

#### A. Ceded Reinsurance Report

Effective January 1, 2017, the Company entered into two reinsurance agreements for selected lines of business. PRAM Captive Insurance Company provided 50% quota share reinsurance for non-Medicare Part D group prescription drug policies. Artex SAC Limited for and on behalf of Fleet ENX Segregated Account provides 100% quota share reinsurance for certain Medicare Part D group prescription drug policies.

Effective April 1, 2020 the reinsurance agreement with PRAM Captive Insurance Company was terminated. All insurance activity related to this product line are underwritten exclusively by EIC since that date.

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company  
NOTES TO FINANCIAL STATEMENTS**

**Section I – General Interrogatories**

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes ( ) No (x)

(2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled directly or indirectly by an insured, a beneficiary, a creditor or any other person not primarily engaged in the insurance business?

Yes ( ) No (x)

**Section 2 – Ceded Reinsurance Report – Part A**

(1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or similar credit?

Yes ( ) No (x)

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes ( ) No (x)

**Section 3 – Ceded Reinsurance Report – Part B**

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate.

\$ (3,770,371)

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or force or which had existing reserves established by the Company as the effective date of the agreement?

Yes ( ) No (x)

B. None.

C. None.

D. None.

E. None.

**24. Retrospectively Rated Contracts & Contracts Subject to Redetermination**

**Medicare Part D**

A. The Company offers Medicare Part D Prescription Benefits Plans. As part of these plans, risk-sharing corridors are established between the providers (the Company) and the Centers for Medicare and Medicaid Services ("CMS"). After all costs are known, a retrospectively rated premium adjustment is developed and paid by (or to) CMS.

B. The Company records accrued retrospective premiums through written premiums. A targeted amount is factored in determining the retrospective adjustments.

C. The amount of the retrospective premium for 2020 was \$241,925,327 which represents 40% of the total net premiums written.

**Group Plans**

A. The Company offers Employer Group Waiver Plans under its Medicare Part D Contract. Certain of these plans have contingent premium clauses based on the plans loss experience compared to targets

# ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company

## NOTES TO FINANCIAL STATEMENTS

established in the group agreement. Accruals are based on annual experience available at the end of the plan year. At December 31, 2020, there has been no accrued for contingent premiums.

- B. The Company records contingent premium payable through written premiums
- C. The amount of net premiums subject to these group contingent premium clauses written by the company at December 31, 2020 was \$10.1 million, which represents 1.7% of the total net premiums written.

### Medical Loss Ratio Rebates Pursuant to the Public Health Service Act

Starting with plan year 2014, the Company was required to report its medical loss ratio and be subject to medical loss ratio and rebate requirements for its Medicare Part D contract. The report was filed with CMS in December 2020 and the medical loss ratio reported was not below the CMS established minimum threshold for regulatory action.

### Risk-Sharing Provisions of the Affordable Care Act (ACA)

The Company only provides coverage under a Medicare Part D Contract and does not provide coverage subject to the ACA risk-sharing provisions.

## **25. Change in Incurred Claims and Claims Adjustment Expenses**

Activity in the reserve for losses and loss adjustment expenses is summarized as follows:

<i>(In Thousands)</i>	<u>2020</u>	<u>2019</u>
Balance as of January 1:	\$ 181,131	\$ 131,320
Incurred related to:		
Current year	585,540	395,446
Prior years	<u>(5,652)</u>	<u>671</u>
Total incurred	<u>579,888</u>	<u>368,060</u>
Paid related to:		
Current year	453,719	214,316
Prior years	<u>175,479</u>	<u>131,990</u>
Total paid	<u>629,198</u>	<u>346,306</u>
Balance as of December 31:	<u><u>\$ 131,821</u></u>	<u><u>\$ 181,131</u></u>

These amounts do not include the LICS, CGDP, or Federal Catastrophic Reinsurance portions of claims that have been or will be reimbursed by CMS or drug manufacturers.

The Company has established an incurred but not reported reserve of \$2.5 million at December 31, 2020. The reserve is based on historical rates of adverse claims development experience.

## **26. Intercompany Pooling Arrangements**

Not applicable at December 31, 2020 and 2019.

## **27. Structured Settlements**

Not applicable at December 31, 2020 and 2019.

## **28. Health Care Receivables**

The Company does not have any health care receivables disclosures at December 31, 2020 or 2019.

## **29. Participating Policies**

Not applicable at December 31, 2020 and 2019.

## **30. Premium Deficiency Reserves**

The Company did not record premium deficiency reserves at December 31, 2020 or 2019.

## **31. Anticipated Subrogation and Other Receivables**

The Company took into account estimated anticipated salvage and subrogation in its determination of the liability for unpaid claims/losses. No reduction in liability was required.

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**GENERAL INTERROGATORIES**

**PART 1 - COMMON INTERROGATORIES**

**GENERAL**

1.1 Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer? Yes [ X ] No [ ]

If yes, complete Schedule Y, Parts 1, 1A and 2.

1.2 If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations? Yes [ X ] No [ ] N/A [ ]

1.3 State Regulating? Ohio.....

1.4 Is the reporting entity publicly traded or a member of a publicly traded group? Yes [ X ] No [ ]

1.5 If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group. 84129.....

2.1 Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity? Yes [ X ] No [ ]

2.2 If yes, date of change: 06/01/2020

3.1 State as of what date the latest financial examination of the reporting entity was made or is being made. 12/31/2016

3.2 State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released. 12/31/2016

3.3 State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date). 02/20/2018

3.4 By what department or departments? Ohio Department of Insurance.....

3.5 Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments? Yes [ ] No [ ] N/A [ X ]

3.6 Have all of the recommendations within the latest financial examination report been complied with? Yes [ ] No [ ] N/A [ X ]

4.1 During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity) receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:

4.11 sales of new business? Yes [ ] No [ X ]

4.12 renewals? Yes [ ] No [ X ]

4.2 During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate, receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of:

4.21 sales of new business? Yes [ ] No [ X ]

4.22 renewals? Yes [ ] No [ X ]

5.1 Has the reporting entity been a party to a merger or consolidation during the period covered by this statement? Yes [ ] No [ X ]

If yes, complete and file the merger history data file with the NAIC.

5.2 If yes, provide the name of the entity, NAIC company code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.

1 Name of Entity	2 NAIC Company Code	3 State of Domicile
.....	.....	.....
.....	.....	.....
.....	.....	.....
.....	.....	.....

6.1 Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended or revoked by any governmental entity during the reporting period? Yes [ ] No [ X ]

6.2 If yes, give full information.....

7.1 Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity? Yes [ ] No [ X ]

7.2 If yes,

7.21 State the percentage of foreign control 0.0 %

7.22 State the nationality(s) of the foreign person(s) or entity(s); or if the entity is a mutual or reciprocal, the nationality of its manager or attorney-in-fact and identify the type of entity(s) (e.g., individual, corporation, government, manager or attorney-in-fact).

1 Nationality	2 Type of Entity
.....	.....
.....	.....
.....	.....

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**GENERAL INTERROGATORIES**

8.1 Is the company a subsidiary of a bank holding company regulated by the Federal Reserve Board? Yes [ ] No [ X ]

8.2 If response to 8.1 is yes, please identify the name of the bank holding company.

8.3 Is the company affiliated with one or more banks, thrifts or securities firms? Yes [ ] No [ X ]

8.4 If response to 8.3 is yes, please provide the names and locations (city and state of the main office) of any affiliates regulated by a federal financial regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Comptroller of the Currency (OCC), the Federal Deposit Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and identify the affiliate's primary federal regulator.

1 Affiliate Name	2 Location (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC

9. What is the name and address of the independent certified public accountant or accounting firm retained to conduct the annual audit?  
Marcum 6685 Beta Dr., Mayfield Village, Ohio 44143.....

10.1 Has the insurer been granted any exemptions to the prohibited non-audit services provided by the certified independent public accountant requirements as allowed in Section 7H of the Annual Financial Reporting Model Regulation (Model Audit Rule), or substantially similar state law or regulation? Yes [ ] No [ X ]

10.2 If the response to 10.1 is yes, provide information related to this exemption:

10.3 Has the insurer been granted any exemptions related to the other requirements of the Annual Financial Reporting Model Regulation as allowed for in Section 18A of the Model Regulation, or substantially similar state law or regulation? Yes [ ] No [ X ]

10.4 If the response to 10.3 is yes, provide information related to this exemption:

10.5 Has the reporting entity established an Audit Committee in compliance with the domiciliary state insurance laws? Yes [ X ] No [ ] N/A [ ]

10.6 If the response to 10.5 is no or n/a, please explain

11. What is the name, address and affiliation (officer/employee of the reporting entity or actuary/consultant associated with an actuarial consulting firm) of the individual providing the statement of actuarial opinion/certification?  
Milliman c/o Courtney R. White, FSA, MAAA, 3424 Peachtree Road NE, Suite 1900, Atlanta, Georgia 30326-1123.....

12.1 Does the reporting entity own any securities of a real estate holding company or otherwise hold real estate indirectly? Yes [ ] No [ X ]

12.11 Name of real estate holding company 0.....

12.12 Number of parcels involved 0.....

12.13 Total book/adjusted carrying value \$.....

12.2 If yes, provide explanation

13. FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES ONLY:

13.1 What changes have been made during the year in the United States manager or the United States trustees of the reporting entity?

13.2 Does this statement contain all business transacted for the reporting entity through its United States Branch on risks wherever located? Yes [ ] No [ ]

13.3 Have there been any changes made to any of the trust indentures during the year? Yes [ ] No [ ]

13.4 If answer to (13.3) is yes, has the domiciliary or entry state approved the changes? Yes [ ] No [ ] N/A [ ]

14.1 Are the senior officers (principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) of the reporting entity subject to a code of ethics, which includes the following standards? Yes [ X ] No [ ]

a. Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

b. Full, fair, accurate, timely and understandable disclosure in the periodic reports required to be filed by the reporting entity;

c. Compliance with applicable governmental laws, rules and regulations;

d. The prompt internal reporting of violations to an appropriate person or persons identified in the code; and

e. Accountability for adherence to the code.

14.11 If the response to 14.1 is no, please explain:

14.2 Has the code of ethics for senior managers been amended? Yes [ ] No [ X ]

14.21 If the response to 14.2 is yes, provide information related to amendment(s).

14.3 Have any provisions of the code of ethics been waived for any of the specified officers? Yes [ ] No [ X ]

14.31 If the response to 14.3 is yes, provide the nature of any waiver(s).

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**GENERAL INTERROGATORIES**

15.1 Is the reporting entity the beneficiary of a Letter of Credit that is unrelated to reinsurance where the issuing or confirming bank is not on the SVO Bank List? Yes [ ] No [ X ]

15.2 If the response to 15.1 is yes, indicate the American Bankers Association (ABA) Routing Number and the name of the issuing or confirming bank of the Letter of Credit and describe the circumstances in which the Letter of Credit is triggered.

1 American Bankers Association (ABA) Routing Number	2 Issuing or Confirming Bank Name	3 Circumstances That Can Trigger the Letter of Credit	4 Amount
.....	.....	.....	.....
.....	.....	.....	.....
.....	.....	.....	.....

**BOARD OF DIRECTORS**

16. Is the purchase or sale of all investments of the reporting entity passed upon either by the board of directors or a subordinate committee thereof? Yes [ X ] No [ ]

17. Does the reporting entity keep a complete permanent record of the proceedings of its board of directors and all subordinate committees thereof? Yes [ X ] No [ ]

18. Has the reporting entity an established procedure for disclosure to its board of directors or trustees of any material interest or affiliation on the part of any of its officers, directors, trustees or responsible employees that is in conflict or is likely to conflict with the official duties of such person? Yes [ X ] No [ ]

**FINANCIAL**

19. Has this statement been prepared using a basis of accounting other than Statutory Accounting Principles (e.g., Generally Accepted Accounting Principles)? Yes [ ] No [ X ]

20.1 Total amount loaned during the year (inclusive of Separate Accounts, exclusive of policy loans): 20.11 To directors or other officers \$.....  
20.12 To stockholders not officers \$.....  
20.13 Trustees, supreme or grand (Fraternal only) \$.....

20.2 Total amount of loans outstanding at the end of year (inclusive of Separate Accounts, exclusive of policy loans): 20.21 To directors or other officers \$.....  
20.22 To stockholders not officers \$.....  
20.23 Trustees, supreme or grand (Fraternal only) \$.....

21.1 Were any assets reported in this statement subject to a contractual obligation to transfer to another party without the liability for such obligation being reported in the statement? Yes [ ] No [ X ]

21.2 If yes, state the amount thereof at December 31 of the current year: 21.21 Rented from others \$.....  
21.22 Borrowed from others \$.....  
21.23 Leased from others \$.....  
21.24 Other \$.....

22.1 Does this statement include payments for assessments as described in the *Annual Statement Instructions* other than guaranty fund or guaranty association assessments? Yes [ ] No [ X ]

22.2 If answer is yes: 22.21 Amount paid as losses or risk adjustment \$.....  
22.22 Amount paid as expenses \$.....  
22.23 Other amounts paid \$.....

23.1 Does the reporting entity report any amounts due from parent, subsidiaries or affiliates on Page 2 of this statement? Yes [ ] No [ X ]

23.2 If yes, indicate any amounts receivable from parent included in the Page 2 amount: \$.....

**INVESTMENT**

24.01 Were all the stocks, bonds and other securities owned December 31 of current year, over which the reporting entity has exclusive control, in the actual possession of the reporting entity on said date? (other than securities lending programs addressed in 24.03) Yes [ X ] No [ ]

24.02 If no, give full and complete information, relating thereto

24.03 For securities lending programs, provide a description of the program including value for collateral and amount of loaned securities, and whether collateral is carried on or off-balance sheet. (an alternative is to reference Note 17 where this information is also provided)

24.04 For the reporting entity's securities lending program, report amount of collateral for conforming programs as outlined in the Risk-Based Capital Instructions. \$.....

24.05 For the reporting entity's securities lending program, report amount of collateral for other programs. \$.....

24.06 Does your securities lending program require 102% (domestic securities) and 105% (foreign securities) from the counterparty at the outset of the contract? Yes [ ] No [ ] NA [ X ]

24.07 Does the reporting entity non-admit when the collateral received from the counterparty falls below 100%? Yes [ ] No [ ] NA [ X ]

24.08 Does the reporting entity or the reporting entity's securities lending agent utilize the Master Securities Lending Agreement (MSLA) to conduct securities lending? Yes [ ] No [ ] NA [ X ]

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**GENERAL INTERROGATORIES**

24.09 For the reporting entity's securities lending program, state the amount of the following as of December 31 of the current year:

24.091 Total fair value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2	\$.....0
24.092 Total book adjusted/carrying value of reinvested collateral assets reported on Schedule DL, Parts 1 and 2	\$.....0
24.093 Total payable for securities lending reported on the liability page	\$.....0

25.1 Were any of the stocks, bonds or other assets of the reporting entity owned at December 31 of the current year not exclusively under the control of the reporting entity or has the reporting entity sold or transferred any assets subject to a put option contract that is currently in force? (Exclude securities subject to Interrogatory 21.1 and 24.03).

Yes [  ] No [  ]

25.2 If yes, state the amount thereof at December 31 of the current year:

25.21 Subject to repurchase agreements	\$.....
25.22 Subject to reverse repurchase agreements	\$.....
25.23 Subject to dollar repurchase agreements	\$.....
25.24 Subject to reverse dollar repurchase agreements	\$.....
25.25 Placed under option agreements	\$.....
25.26 Letter stock or securities restricted as to sale – excluding FHLB Capital Stock	\$.....
25.27 FHLB Capital Stock	\$.....
25.28 On deposit with states	\$..... 4,931,941
25.29 On deposit with other regulatory bodies	\$.....
25.30 Pledged as collateral – excluding collateral pledged to an FHLB	\$.....
25.31 Pledged as collateral to FHLB – including assets backing funding agreements	\$.....
25.32 Other	\$.....

25.3 For category (25.26) provide the following:

1 Nature of Restriction	2 Description	3 Amount

26.1 Does the reporting entity have any hedging transactions reported on Schedule DB?

Yes [  ] No [  ]

26.2 If yes, has a comprehensive description of the hedging program been made available to the domiciliary state? If no, attach a description with this statement.

Yes [  ] No [  ] N/A [  ]

LINES 26.3 through 26.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY:

26.3 Does the reporting entity utilize derivatives to hedge variable annuity guarantees subject to fluctuations as a result of interest rate sensitivity?

Yes [  ] No [  ]

26.4 If the response to 26.3 is YES, does the reporting entity utilize:

26.41 Special accounting provision of SSAP No. 108	Yes [ <input type="checkbox"/> ] No [ <input type="checkbox"/> ]
26.42 Permitted accounting practice	Yes [ <input type="checkbox"/> ] No [ <input type="checkbox"/> ]
26.43 Other accounting guidance	Yes [ <input type="checkbox"/> ] No [ <input type="checkbox"/> ]

26.5 By responding YES to 26.41 regarding utilizing the special accounting provisions of SSAP No. 108, the reporting entity attests to the following:

Yes [  ] No [  ]

- The reporting entity has obtained explicit approval from the domiciliary state.
- Hedging strategy subject to the special accounting provisions is consistent with the requirements of VM-21.
- Actuarial certification has been obtained which indicates that the hedging strategy is incorporated within the establishment of VM-21 reserves and provides the impact of the hedging strategy within the Actuarial Guideline Conditional Tail Expectation Amount.
- Financial Officer Certification has been obtained which indicates that the hedging strategy meets the definition of a Clearly Defined Hedging Strategy within VM-21 and that the Clearly Defined Hedging Strategy is the hedging strategy being used by the company in its actual day-to-day risk mitigation efforts.

27.1 Were any preferred stocks or bonds owned as of December 31 of the current year mandatorily convertible into equity, or, at the option of the issuer, convertible into equity?

Yes [  ] No [  ]

27.2 If yes, state the amount thereof at December 31 of the current year.

\$.....

28. Excluding items in Schedule E – Part 3 – Special Deposits, real estate, mortgage loans and investments held physically in the reporting entity's offices, vaults or safety deposit boxes, were all stocks, bonds and other securities, owned throughout the current year held pursuant to a custodial agreement with a qualified bank or trust company in accordance with Section 1, III – General Examination Considerations, F. Outsourcing of Critical Functions, Custodial or Safekeeping agreements of the NAIC *Financial Condition Examiners Handbook*?

Yes [  ] No [  ]

28.01 For agreements that comply with the requirements of the NAIC *Financial Condition Examiners Handbook*, complete the following:

1 Name of Custodian(s)	2 Custodian's Address
Huntington National Bank.....	300 Market Street, Akron, OH 44308.....

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**GENERAL INTERROGATORIES**

28.02 For all agreements that do not comply with the requirements of the NAIC *Financial Condition Examiners Handbook*, provide the name, location and a complete explanation:

1 Name(s)	2 Location(s)	3 Complete Explanation(s)

28.03 Have there been any changes, including name changes, in the custodian(s) identified in 28.01 during the current year?

Yes [ ] No [ X ]

28.04 If yes, give full and complete information relating thereto:

1 Old Custodian	2 New Custodian	3 Date of Change	4 Reason

28.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. [“...that have access to the investment accounts”; “...handle securities”]

1 Name of Firm or Individual	2 Affiliation
Internally Managed.....	.....
.....	.....
.....	.....

28.0597 For those firms/individuals listed in the table for Question 28.05, do any firms/individuals unaffiliated with the reporting entity (i.e., designated with a “U”) manage more than 10% of the reporting entity’s invested assets?

Yes [ ] No [ X ]

28.0598 For firms/individuals unaffiliated with the reporting entity (i.e., designated with a “U”) listed in the table for Question 28.05, does the total assets under management aggregate to more than 50% of the reporting entity’s invested assets?

Yes [ ] No [ X ]

28.06 For those firms or individuals listed in the table for 28.05 with an affiliation code of “A” (affiliated) or “U” (unaffiliated), provide the information for the table below.

1 Central Registration Depository Number	2 Name of Firm or Individual	3 Legal Entity Identifier (LEI)	4 Registered With	5 Investment Management Agreement (IMA) Filed
.....	.....	.....	.....	.....
.....	.....	.....	.....	.....
.....	.....	.....	.....	.....

29.1 Does the reporting entity have any diversified mutual funds reported in Schedule D - Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5 (b) (1)])?

Yes [ ] No [ X ]

29.2 If yes, complete the following schedule:

1 CUSIP #	2 Name of Mutual Fund	3 Book/Adjusted Carrying Value
.....	.....	.....
.....	.....	.....
.....	.....	.....
29.2999 TOTAL		0

29.3 For each mutual fund listed in the table above, complete the following schedule:

1 Name of Mutual Fund (from above table)	2 Name of Significant Holding of the Mutual Fund	3 Amount of Mutual Fund’s Book/Adjusted Carrying Value Attributable to the Holding	4 Date of Valuation
.....	.....	.....	.....
.....	.....	.....	.....
.....	.....	.....	.....
.....	.....	.....	.....

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**GENERAL INTERROGATORIES**

30. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1 Statement (Admitted) Value	2 Fair Value	3 Excess of Statement over Fair Value (-), or Fair Value over Statement (+)
30.1 Bonds.....	6,997,807	7,222,393	224,586
30.2 Preferred Stocks.....	0	0	0
30.3 Totals	6,997,807	7,222,393	224,586

30.4 Describe the sources or methods utilized in determining the fair values:

U.S. Department of the Treasury - Treasury Direct.....

Yes [ ] No [ X ]

31.1 Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?

Yes [ ] No [ ]

31.2 If the answer to 31.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?

31.3 If the answer to 31.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:

32.1 Have all the filing requirements of the *Purposes and Procedures Manual of the NAIC Investment Analysis Office* been followed?

Yes [ X ] No [ ]

32.2 If no, list exceptions:

33. By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:

a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.  
b. Issuer or obligor is current on all contracted interest and principal payments.  
c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.

Has the reporting entity self-designated 5GI securities?

Yes [ ] No [ X ]

34. By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:

a. The security was purchased prior to January 1, 2018.  
b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.  
c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as an NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.  
d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.

Has the reporting entity self-designated PLGI securities?

Yes [ ] No [ X ]

35. By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund:

a. The shares were purchased prior to January 1, 2019.  
b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.  
c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.  
d. The fund only or predominantly holds bonds in its portfolio.  
e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.  
f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.

Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?

Yes [ ] No [ X ]

36. By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following:

a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.  
b. If the investment is with a nonrelated party or nonaffiliated then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.  
c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.  
d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 36.a -36.c are reported as long-term investments.

Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?

Yes [ ] No [ ] NA [ X ]

**OTHER**

37.1 Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any? \$ .....

37.2 List the name of the organization and the amount paid if any such payment represented 25% or more of the total payments to trade associations, service organizations, and statistical or rating bureaus during the period covered by this statement.

1 Name	2 Amount Paid
.....	\$.....
.....	\$.....
.....	\$.....

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**GENERAL INTERROGATORIES**

38.1 Amount of payments for legal expenses, if any?

\$ ..... 1,084,279

38.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for legal expenses during the period covered by this statement.

1 Name	2 Amount Paid
Sidley Austin LLP.....	\$.....715,658

39.1 Amount of payments for expenditures in connection with matters before legislative bodies, officers, or departments of government, if any? \$ .....

39.2 List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expenditures in connection with matters before legislative bodies, officers, or departments of government during the period covered by this statement.

1 Name	2 Amount Paid
.....	.....

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**GENERAL INTERROGATORIES**

**PART 2 - HEALTH INTERROGATORIES**

1.1 Does the reporting entity have any direct Medicare Supplement Insurance in force? Yes [ ] No [ X ]  
 1.2 If yes, indicate premium earned on U.S. business only. \$ ..... 0  
 1.3 What portion of Item (1.2) is not reported on the Medicare Supplement Insurance Experience Exhibit? ..... \$ .....  
 1.31 Reason for excluding .....  
 1.4 Indicate amount of earned premium attributable to Canadian and/or Other Alien not included in Item (1.2) above \$ .....  
 1.5 Indicate total incurred claims on all Medicare Supplement insurance. \$ ..... 0  
 1.6 Individual policies:  
 Most current three years:  
 1.61 Total premium earned \$ ..... 0  
 1.62 Total incurred claims \$ ..... 0  
 1.63 Number of covered lives ..... 0  
 All years prior to most current three years:  
 1.64 Total premium earned \$ ..... 0  
 1.65 Total incurred claims \$ ..... 0  
 1.66 Number of covered lives ..... 0  
 1.7 Group policies:  
 Most current three years:  
 1.71 Total premium earned \$ ..... 0  
 1.72 Total incurred claims \$ ..... 0  
 1.73 Number of covered lives ..... 0  
 All years prior to most current three years:  
 1.74 Total premium earned \$ ..... 0  
 1.75 Total incurred claims \$ ..... 0  
 1.76 Number of covered lives ..... 0

2. Health Test:

	1 Current Year	2 Prior Year
2.1 Premium Numerator	\$ ..... 590,533,060	\$ ..... 424,976,399
2.2 Premium Denominator	\$ ..... 590,533,060	\$ ..... 424,976,399
2.3 Premium Ratio (2.1/2.2)	..... 1.000	..... 1.000
2.4 Reserve Numerator	\$ ..... 128,517,229	\$ ..... 178,682,051
2.5 Reserve Denominator	\$ ..... 128,517,229	\$ ..... 178,682,051
2.6 Reserve Ratio (2.4/2.5)	..... 1.000	..... 1.000

3.1 Has the reporting entity received any endowment or gift from contracting hospitals, physicians, dentists, or others that is agreed will be returned when, as and if the earnings of the reporting entity permits? Yes [ ] No [ X ]  
 3.2 If yes, give particulars:

4.1 Have copies of all agreements stating the period and nature of hospitals', physicians', and dentists' care offered to subscribers and dependents been filed with the appropriate regulatory agency? Yes [ ] No [ X ]  
 4.2 If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these agreements include additional benefits offered? Yes [ ] No [ X ]  
 5.1 Does the reporting entity have stop-loss reinsurance? Yes [ ] No [ X ]  
 5.2 If no, explain:

5.3 Maximum retained risk (see instructions) 5.31 Comprehensive Medical \$ .....  
 5.32 Medical Only \$ .....  
 5.33 Medicare Supplement \$ .....  
 5.34 Dental and Vision \$ .....  
 5.35 Other Limited Benefit Plan \$ .....  
 5.36 Other \$ .....

6. Describe arrangement which the reporting entity may have to protect subscribers and their dependents against the risk of insolvency including hold harmless provisions, conversion privileges with other carriers, agreements with providers to continue rendering services, and any other agreements:

7.1 Does the reporting entity set up its claim liability for provider services on a service date basis? Yes [ X ] No [ ]  
 7.2 If no, give details

8. Provide the following information regarding participating providers:

8.1 Number of providers at start of reporting year	..... 61,211
8.2 Number of providers at end of reporting year	..... 60,946

9.1 Does the reporting entity have business subject to premium rate guarantees? ..... Yes [ ] No [ X ]  
 9.2 If yes, direct premium earned:

9.21 Business with rate guarantees between 15-36 months	.....
9.22 Business with rate guarantees over 36 months	.....

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**GENERAL INTERROGATORIES**

**PART 2 - HEALTH INTERROGATORIES**

10.1 Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts? Yes [ ] No [ X ]  
 10.2 If yes:

10.21 Maximum amount payable bonuses	\$.....
10.22 Amount actually paid for year bonuses	\$.....
10.23 Maximum amount payable withholds	\$.....
10.24 Amount actually paid for year withholds	\$.....

11.1 Is the reporting entity organized as:  
 11.12 A Medical Group/Staff Model, Yes [ ] No [ X ]  
 11.13 An Individual Practice Association (IPA), or, Yes [ ] No [ X ]  
 11.14 A Mixed Model (combination of above)? Yes [ ] No [ X ]  
 11.2 Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirements?  
 11.3 If yes, show the name of the state requiring such minimum capital and surplus.  
 11.4 If yes, show the amount required.  
 11.5 Is this amount included as part of a contingency reserve in stockholder's equity?  
 11.6 If the amount is calculated, show the calculation

12. List service areas in which reporting entity is licensed to operate:

1 Name of Service Area	
All 50 states plus District of Columbia.....	
Guam.....	
Puerto Rico.....	

13.1 Do you act as a custodian for health savings accounts? Yes [ ] No [ X ]  
 13.2 If yes, please provide the amount of custodial funds held as of the reporting date. \$.....  
 13.3 Do you act as an administrator for health savings accounts? Yes [ ] No [ X ]  
 13.4 If yes, please provide the balance of the funds administered as of the reporting date. \$.....

14.1 Are any of the captive affiliates reported on Schedule S, Part 3 as authorized reinsurers? Yes [ ] No [ N/A [ X ] ]  
 14.2 If the answer to 14.1 is yes, please provide the following:

1 Company Name	2 NAIC Company Code	3 Domiciliary Jurisdiction	4 Reserve Credit	Assets Supporting Reserve Credit		
				5 Letters of Credit	6 Trust Agreements	7 Other

15. Provide the following for individual ordinary life insurance\* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded).

15.1 Direct Premium Written	\$.....
15.2 Total Incurred Claims	\$.....
15.3 Number of Covered Lives	.....

*Ordinary Life Insurance Includes						
Term (whether full underwriting, limited underwriting, jet issue, "short form app")						
Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")						
Variable Life (with or without secondary guarantee)						
Universal Life (with or without secondary guarantee)						
Variable Universal Life (with or without secondary guarantee)						

16. Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states? Yes [ X ] No [ ]  
 16.1 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity? Yes [ ] No [ ]

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**FIVE - YEAR HISTORICAL DATA**

	1 2020	2 2019	3 2018	4 2017	5 2016
<b>Balance Sheet (Pages 2 and 3)</b>					
1. Total admitted assets (Page 2, Line 28)	551,003,295	704,270,210	496,667,034	428,859,470	309,925,001
2. Total liabilities (Page 3, Line 24)	476,062,704	649,488,313	444,845,802	381,400,312	260,335,335
3. Statutory minimum capital and surplus requirement	15,431,623	20,195,311	15,075,765	27,186,474	18,962,017
4. Total capital and surplus (Page 3, Line 33)	74,940,591	54,781,897	51,821,232	47,459,158	49,589,666
<b>Income Statement (Page 4)</b>					
5. Total revenues (Line 8)	590,533,060	424,976,399	393,701,833	170,332,618	235,910,944
6. Total medical and hospital expenses (Line 18)	576,111,823	392,260,079	362,616,956	155,786,950	223,083,334
7. Claims adjustment expenses (Line 20)	3,775,693	3,856,850	5,442,721	6,179,335	4,887,739
8. Total administrative expenses (Line 21)	33,006,445	20,049,571	20,694,675	8,844,377	9,818,327
9. Net underwriting gain (loss) (Line 24)	(22,360,901)	8,809,899	4,947,481	(478,044)	(1,878,456)
10. Net investment gain (loss) (Line 27)	199,506	973,927	608,765	110,872	80,166
11. Total other income (Lines 28 plus 29)	(2,490,000)	(1,762,500)	(2,700,000)	(2,200,000)	(1,434,319)
12. Net income or (loss) (Line 32)	(24,651,395)	6,257,092	1,581,830	(2,567,172)	(3,393,464)
<b>Cash Flow (Page 6)</b>					
13. Net cash from operations (Line 11)	91,418,702	(121,604,021)	19,848,765	(76,937,109)	46,217,754
<b>Risk-Based Capital Analysis</b>					
14. Total adjusted capital	74,940,591	54,781,897	51,821,232	47,459,158	49,589,666
15. Authorized control level risk-based capital	17,225,913	12,589,893	9,245,957	7,604,162	7,057,877
<b>Enrollment (Exhibit 1)</b>					
16. Total members at end of period (Column 5, Line 7)	958,026	721,781	598,216	402,470	379,799
17. Total members months (Column 6, Line 7)	10,909,167	8,020,563	6,684,952	4,277,255	4,555,133
<b>Operating Percentage (Page 4)</b>					
(Item divided by Page 4, sum of Lines 2, 3, and 5) x 100.0					
18. Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19. Total hospital and medical plus other non-health (Lines 18 plus Line 19)	97.6	92.3	92.1	91.5	94.6
20. Cost containment expenses	0.0	0.0	0.0	0.0	0.0
21. Other claims adjustment expenses	0.6	0.9	1.4	3.6	2.1
22. Total underwriting deductions (Line 23)	103.8	97.9	98.7	100.3	100.8
23. Total underwriting gain (loss) (Line 24)	(3.8)	2.1	1.3	(0.3)	(0.8)
<b>Unpaid Claims Analysis</b>					
(U&I Exhibit, Part 2B)					
24. Total claims incurred for prior years (Line 13, Col. 5)	173,029,953	128,524,448	25,812,272	24,417,528	25,366,823
25. Estimated liability of unpaid claims – [prior year (Line 13, Col. 6)]	178,682,051	127,853,216	25,761,504	24,916,227	24,283,432
<b>Investments in Parent, Subsidiaries and Affiliates</b>					
26. Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	0
27. Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)	0	0	0	0	0
28. Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0	0	0	0
29. Affiliated short-term investments (subtotal included in Sch. DA Verification, Col. 5, Line 10)	0	0	0	0	0
30. Affiliated mortgage loans on real estate	0	0	0	0	0
31. All other affiliated	0	0	0	0	0
32. Total of above Lines 26 to 31	0	0	0	0	0
33. Total investment in parent included in Lines 26 to 31 above					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure requirements of SSAP No. 3 - *Accounting Changes and Correction of Errors?* Yes  No

If no, please explain

**ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Elixir Insurance Company**

**SCHEDULE T - PREMIUMS AND OTHER CONSIDERATIONS**

Allocated by States and Territories


State, Etc.	1 Active Status (a)	Direct Business Only							
		2 Accident & Health Premiums	3 Medicare Title XVIII	4 Medicaid Title XIX	5 Federal Employees Health Benefits Plan Premiums	6 Life & Annuity Premiums & Other Considerations	7 Property/Casualty Premiums	8 Total Columns 2 Through 7	9 Deposit-Type Contracts
1. Alabama	AL	2,047,320						2,047,320	0
2. Alaska	AK	1,911,462						1,911,462	0
3. Arizona	AZ	6,439,797						6,439,797	0
4. Arkansas	AR	278,017						278,017	0
5. California	CA	54,410,774						54,410,774	0
6. Colorado	CO	10,412,662						10,412,662	0
7. Connecticut	CT	7,842,391						7,842,391	0
8. Delaware	DE	4,492,331						4,492,331	0
9. District of Columbia	DC	5,057,742						5,057,742	0
10. Florida	FL	5,309,549						5,309,549	0
11. Georgia	GA	17,940,325						17,940,325	0
12. Hawaii	HI	31,960						31,960	0
13. Idaho	ID	3,930,807						3,930,807	0
14. Illinois	IL	21,174,006						21,174,006	0
15. Indiana	IN	4,677,087						4,677,087	0
16. Iowa	IA	856,471						856,471	0
17. Kansas	KS	469,751						469,751	0
18. Kentucky	KY	3,396,962						3,396,962	0
19. Louisiana	LA	783,397						783,397	0
20. Maine	ME	4,420,904						4,420,904	0
21. Maryland	MD	19,508,721						19,508,721	0
22. Massachusetts	MA	18,362,860						18,362,860	0
23. Michigan	MI	27,818,742						27,818,742	0
24. Minnesota	MN	565,015						565,015	0
25. Mississippi	MS	9,757,569						9,757,569	0
26. Missouri	MO	810,718						810,718	0
27. Montana	MT	300,145						300,145	0
28. Nebraska	NE	1,434,361						1,434,361	0
29. Nevada	NV	360,799						360,799	0
30. New Hampshire	NH	6,991,043						6,991,043	0
31. New Jersey	NJ	2,732,370						2,732,370	0
32. New Mexico	NM	3,736,707						3,736,707	0
33. New York	NY	43,502,378						43,502,378	0
34. North Carolina	NC	25,852,263						25,852,263	0
35. North Dakota	ND	148,645						148,645	0
36. Ohio	OH	116,107,967						116,107,967	0
37. Oklahoma	OK	430,975						430,975	0
38. Oregon	OR	16,343,455						16,343,455	0
39. Pennsylvania	PA	56,198,417						56,198,417	0
40. Rhode Island	RI	2,905,633						2,905,633	0
41. South Carolina	SC	21,962,545						21,962,545	0
42. South Dakota	SD	156,292						156,292	0
43. Tennessee	TN	3,886,182						3,886,182	0
44. Texas	TX	13,256,220						13,256,220	0
45. Utah	UT	2,280,035						2,280,035	0
46. Vermont	VT	4,379,431						4,379,431	0
47. Virginia	VA	5,767,483						5,767,483	0
48. Washington	WA	25,697,715						25,697,715	0
49. West Virginia	WV	6,247,023						6,247,023	0
50. Wisconsin	WI	9,709,229						9,709,229	0
51. Wyoming	WY	194,931						194,931	0
52. American Samoa	AS	0						0	0
53. Guam	GU	40,011						40,011	0
54. Puerto Rico	PR	47,099						47,099	0
55. U.S. Virgin Islands	VI	0						0	0
56. Northern Mariana Islands	MP	0						0	0
57. Canada	CAN	0						0	0
58. Aggregate other alien	OT	0	0	0	0	0	0	0	0
59. Subtotal		603,376,694	0	0	0	0	0	603,376,694	0
60. Reporting entity contributions for Employee Benefit Plans		XXX						0	0
61. Total (Direct Business)		XXX	603,376,694	0	0	0	0	603,376,694	0
<b>DETAILS OF WRITE-INS</b>									
58001.		XXX							
58002.		XXX							
58003.		XXX							
58998.	Summary of remaining write-ins for Line 58 from overflow page.	0	0	0	0	0	0	0	0
58999.	Totals (Lines 58001 through 58003 plus 58998) (Line 58 above)	XXX	0	0	0	0	0	0	0

(a) Active Status Counts

L – Licensed or Chartered – Licensed insurance carrier or domiciled RRG ..... 53 R – Registered – Non-domiciled RRGs ..... 0  
E – Eligible – Reporting entities eligible or approved to write surplus lines in the state ..... 0 Q – Qualified – Qualified or accredited reinsurer ..... 0  
N – None of the above – Not allowed to write business in the state lines in the state ..... 4

(b) **Explanation of basis of allocation of premiums by states, etc.**

Premiums by residency. Retrospective allocated proportionately.



## RITE AID CORPORATION AFFILIATES/SUBSIDIARIES

Company (Name in which such subsidiary conducts business if other than corporate Incorporation name):	State of or Organization
112 Burleigh Avenue Norfolk, LLC .....	Virginia
1515 West State Street Boise, Idaho, LLC .....	Delaware
1740 Associates, LLC .....	Michigan
3581 Carter Hill Road—Montgomery Corp. ....	Alabama
4042 Warrensville Center Road—Warrensville Ohio, Inc. ....	Ohio
5277 Associates, Inc. ....	Washington
5600 Superior Properties, Inc. ....	Ohio
657 - 659 Broad St. Corp. ....	New Jersey
Advance Benefits, LLC .....	Florida
Apex Drug Stores, Inc. ....	Michigan
Ascend Health Technology, LLC .....	Delaware
Broadview and Wallings—Broadview Heights Ohio, Inc. ....	Ohio
Eagle Managed Care Corp. ....	Delaware
Eckerd Corporation .....	Delaware
EDC Drug Stores, Inc. ....	North Carolina
England Street—Asheland Corporation .....	Virginia
EOL[LU Insurance Company .....	Ohio
GDF, Inc. ....	Maryland
Genovese Drug Stores, Inc. ....	Delaware
Harco, Inc. ....	Alabama
Health Dialog Services Corporation .....	Delaware
JCG (PJC) USA, LLC .....	Delaware
JCG Holdings (USA), Inc. ....	Delaware
K&B Alabama Corporation .....	Alabama
K&B Louisiana Corporation .....	Louisiana
K&B Mississippi Corporation .....	Mississippi
K&B Services, Incorporated .....	Louisiana
K&B Tennessee Corporation .....	Tennessee
K&B Texas Corporation .....	Texas
K&B, Incorporated .....	Delaware
Keystone Centers, Inc. ....	Pennsylvania
Lakehurst and Broadway Corporation .....	New Jersey
Maxi Drug North, Inc. ....	Delaware
Maxi Drug South, L.P. ....	Delaware
Maxi Drug, Inc. ....	Delaware
Maxi Green, Inc. ....	Vermont
Munson & Andrews, LLC .....	Delaware
Name Rite, LLC .....	Delaware
Orchard Pharmaceutical Services, LLC .....	Ohio
P.J.C. Distribution, Inc. ....	Delaware
P.J.C. Realty Co., Inc. ....	Delaware
Patton Drive and Navy Boulevard Property Corporation .....	Florida
PDS-1 Michigan, Inc. ....	Michigan
Perry Distributors, Inc. ....	Michigan
Perry Drug Stores Inc. ....	Michigan
PJC Dorchester Realty LLC .....	Delaware
PJC East Lyme Realty LLC .....	Delaware
PJC Haverhill Realty LLC .....	Delaware
PJC Hermitage Realty LLC .....	Delaware
PJC Hyde Park Realty LLC .....	Delaware
PJC Lease Holdings, Inc. ....	Delaware
PJC Manchester Realty LLC .....	Delaware
PJC Mansfield Realty LLC .....	Delaware
PJC New London Realty LLC .....	Delaware
PJC of Massachusetts, Inc. ....	Massachusetts
PJC of Rhode Island, Inc. ....	Rhode Island
PJC of Vermont, Inc. ....	Vermont
PJC Peterborough Realty LLC .....	Delaware
PJC Providence Realty LLC .....	Delaware

PJC Realty MA, Inc. ....	Massachusetts
PJC Realty N.E. LLC .....	Delaware
PJC Revere Realty LLC .....	Delaware
PJC Special Realty Holdings, Inc. ....	Delaware
Ram—Utica, Inc. ....	Michigan
RDS Detroit, Inc. ....	Michigan
READ's Inc. ....	Maryland
RediClinic LLC.....	Delaware
Rite Aid Drug Palace, Inc. ....	Delaware
Rite Aid Hdqtrs. Corp. ....	Delaware
Rite Aid Hdqtrs. Funding, Inc. ....	Delaware
Rite Aid Lease Management Company .....	California
Rite Aid of Alabama, Inc. ....	Alabama
Rite Aid of Connecticut, Inc. ....	Connecticut
Rite Aid of Delaware, Inc. ....	Delaware
Rite Aid of Florida, Inc. ....	Florida
Rite Aid of Georgia, Inc. ....	Georgia
Rite Aid of Illinois, Inc. ....	Illinois
Rite Aid of Indiana, Inc. ....	Indiana
Rite Aid of Kentucky, Inc. ....	Kentucky
Rite Aid of Maine, Inc. ....	Maine
Rite Aid of Maryland, Inc. ....	Maryland
Rite Aid of Massachusetts, Inc. ....	Massachusetts
Rite Aid of Michigan, Inc. ....	Michigan
Rite Aid of New Hampshire, Inc. ....	New Hampshire
Rite Aid of New Jersey, Inc. ....	New Jersey
Rite Aid of New York, Inc. ....	New York
Rite Aid of North Carolina, Inc. ....	North Carolina
Rite Aid of Ohio, Inc. ....	Ohio
Rite Aid of Pennsylvania, Inc. ....	Pennsylvania
Rite Aid of South Carolina, Inc. ....	South Carolina
Rite Aid of Tennessee, Inc. ....	Tennessee
Rite Aid of Vermont, Inc. ....	Vermont
Rite Aid of Virginia, Inc. ....	Virginia
Rite Aid of Washington, D.C., Inc. ....	Washington DC
Rite Aid of West Virginia, Inc. ....	West Virginia
Rite Aid Online Store Inc. ....	Delaware
Rite Aid Payroll Management Inc. ....	Delaware
Rite Aid Realty Corp. ....	Delaware
Rite Aid Rome Distribution Center, Inc. ....	New York
Rite Aid Services, LLC .....	Delaware
Rite Aid Specialty Pharmacy LLC.....	Delaware
Rite Aid Transport, Inc. ....	Delaware
Rite Fund, Inc. ....	Delaware
Rite Investments Corp. ....	Delaware
Rite Investments Corp., LLC .....	Delaware
Rx Choice, Inc. ....	Delaware
Rx Initiatives, LLC .....	Utah
Silver Springs Road—Baltimore, Maryland/One, LLC .....	Delaware
Silver Springs Road—Baltimore, Maryland/Two, LLC .....	Delaware
The Jean Coutu Group (PJC) USA, Inc. ....	Delaware
The Lane Drug Company.....	Ohio
Thrift Drug Inc. ....	Delaware
Thrifty Corporation .....	California
Thrifty PayLess, Inc. ....	California
Tyler and Sanders Roads—Birmingham, Alabama, LLC .....	Delaware